Feeds:
Posts
Comments

Archive for the ‘Cancer-Immune Interactions’ Category

Real Time Conferecence Coverage: Advancing Precision Medicine Conference Philadelphia PA November 1,2 2024  Deliverables

Curator: Stephen J. Williams, Ph.D.

Below are deliverables in form of real Time conference coverage from the Advancing Precision Medicine Confererence held this year in Philadelphia, PA.  The meeting brought together scientists and clinicians to discuss the challenges faced in implementing genomics and proteomics into precision medicine decision making workflow.  As summarized by a future release at the 2025 ASCO, there are many issues and hindrances to incorporating data obtained from sequencing to make a personalized medicine strategy.  The meeting focused on two main disease states: oncology and cardiovascular however most of  the live meeting notes are from the oncology tract.  In general it was discussed there are three areas which need to be addressed to correctly and more frequently incorporate precision medicine and genomic panel testing into clinical decision making workflow:

  1.  access to testing panels and testing methodology for both doctors and patients
  2. expert interpretation of results including algorithms needed to analyze the data
  3. more education of molecular biology and omics data and methodology in medical school to address knowledge gaps between clinicians and scientists

The issues can be summarized by a JCO report to ASCO in 2022:

 Helen Sadik, PhDDaryl Pritchard, PhD https://orcid.org/0000-0003-2675-0371 dpritchard@personalizedmedicinecoalition.orgDerry-Mae Keeling, BScFrank Policht, PhDPeter Riccelli, PhDGretta Stone, BSKira Finkel, MSPHJeff Schreier, MBA, and Susanne Munksted, MS.  Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer. 2022: JCO Precision Oncology; Volume 6. https://doi.org/10.1200/PO.22.00246

Personalized medicine presents new opportunities for patients with cancer. However, many patients do not receive the most effective personalized treatments because of challenges associated with integrating predictive biomarker testing into clinical care. Patients are lost at various steps along the precision oncology pathway because of operational inefficiencies, limited understanding of biomarker strategies, inappropriate testing result usage, and access barriers. We examine the impact of various clinical practice gaps associated with diagnostic testing-informed personalized medicine strategies on the treatment of advanced non–small-cell lung cancer (aNSCLC).

The authors used a  Diaceutics’ Data Repository, a multisource database including commercial and Medicare claims and laboratory data from over 500,000 patients with non–small-cell lung cancer in the United States. They  analyzed the number of patients with newly diagnosed aNSCLC who could have, but did not, benefit from a personalized treatment. The analysis was focused on identifying the gaps and at which steps during care did gaps existed which precipitated either lack of use of precision medicine testing or incorrect interpretation of results.

Their conclusions were alarming:

Most patients with aNSCLC eligible for precision oncology treatments do not benefit from them because of clinical practice gaps. This finding is likely reflective of similar gaps in other cancer types. An increased understanding of the impact of each practice gap can inform strategies to improve the delivery of precision oncology, helping to fully realize the promise of personalized medicine.

The links to the live meeting notes are given below and collection of tweets follow (please note this meeting did not have a Twitter hashtag)

Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-advancing-precision-medicine-annual-conference-philadelphia-pa-november-12-2024/

Real Time Coverage Morning Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-morning-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-1-2024/

Real Time Coverage Afternoon Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-afternoon-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-1-2024/ 

Real Time Coverage Morning Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 2 2024

https://pharmaceuticalintelligence.com/2024/11/04/real-time-coverage-morning-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-2-2024/ 

Tweet Collection

Tweet Collection Advancing Precision Medicine Conference November 1,2 2024 Philadelphia PA

 

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Early Morning Session Track 1 October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

 

8:55 – 10:35

SESSION 1

Precision For All:

Global Access, Real Cases, and Implementation Science

 

8:55-9:15

Results and Future Direction from WIN’s Data Science Paper

Razelle Kurzrock, MD

9:15-9:55

When Precision Gets Personal: WIN Consortium International Molecular Tumor Board Live

Andrea Ferreira-Gonzalez
Razelle Kurzrock, MD

Razelle Kurzrock, MD, FACP, Chief Medical Officer, WIN Consortium; Professor of Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, MCW Cancer Center and Linda T. & John A. Mellowes Center for Genomic Sciences and Precision Medicine

Notes from Live Tumor Board from Live Tweets

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

Tumor board Live . Oncologists don’t always accept tumor board recommendations based on molecular profiling… Dr Baptiste at first felt constrained to use single agent but WINTER combo trial with molec profiling better

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

Pemetrexemed not always working but MTAP inhibitions may work

Tumor board Live… Discussion of ovarian cancer case women first presented with CRC BRCA mut but failed PARP inhibitor board is looking at immunotherapy NGS IHC performed

#WINconsortium

Fusions being detected by RNAseq at rate of 100 per month

Tumor board Live…. Theranostics are becoming part of molec tumor board … Radio labeled dual diagnostic therapeutic antibodies

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

SESSION 2

Expanding the Precision Frontier

9:55-10:25

Precision Oncology in the Immunotherapy Era: Biomarkers and Clinical Trial Innovation

Razelle Kurzrock, MD

Lillian Siu, MD, President, AACR 2025-2026; Director, Phase I Clinical Trials Program; Co-Director, Robert and Maggie Bras and Family Drug Development Program Clinical Lead, Tumor Immunotherapy Program; BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre Professor of Medicine, University of Toronto

  • Princess Margaret CC went to Merck got pembrolizumab from them but built a team platform of clinicians and scientists to work on INSPIRE trial
  • $11 million of grants, 13 major papers, great team science
  • did ctDNA from liquid biopsy and also looked at methylation patterns in cfDNA
  • looked at IFN stimulation and outcome to pembrolizumab
  • retro transposable elements found in INSPIRE program, maybe a predictor of immune sensitivity
  • they were able to correlate some of their findings with spatial omics
  • using spatial data they could look at hot versus cold head and neck cancer
  •  factors for response to immunotherapy: TMB, t cell infiltrate,  PDL1 etc
  • using AI with IHC slides as well as NGS data sets
  • as clinical trials become multiomics and AI with multiomics platforms data sharing will be critical for success

10:25 – 10:35

The Microbiome and Its Role in Cancer Development and Treatment Response

Razelle Kurzrock, MD

Sabine Hazan, MD, CEO, Ventura Clinical Trials; CEO, Progenabiome

  • microbiome research at the infancy so we don’t know much when comes to oncology
  • we need to compare microbiome between persons using NGS and other omics
  • we all have different microbiome even though microbiome ‘healthy’
  • lots of factors affect microbiome including surgery
  • families are similar in their microbiome but when looking at Alzheimers there are differences
  • first lab to find whole COVID in the stools
  • virus was different in different people, difference spike proteins. Virus mutates from lung to stool (gut)
  • in intrafamily patients had different microbiome upon COVID infection
  • bifodobacteria was found as a major part of microbiome altered in COVID but also lots of other diseases
  • lots of examples of host microbial symbiosis
  • they had an instance with throat tumor treated with microbiome and tumor receded without chemo
  • in a glioblastoma microbiome adjustment helped but changed positive response to immunotherapy

Read Full Post »

Dr. Zelig Eshhar, A Founding Father of CAR-T cell Immunotherapy passed away on 7/4/2025

Reporter: Aviva Lev-Ari, PhD, RN

Professor Zelig Eshhar
The Marshall and Renette Ezralow Professor of Chemical and Cellular Immunology

Weizmann Institute
We, the Weizmann Institute of Science community, deeply mourn the passing of Prof. Zelig Eshhar of the Department of Immunology and Regenerative Biology. Prof. Eshhar was a trailblazing scientist in the field of cancer immunotherapy, a recipient of the Israel Prize in Life Science, and an acclaimed researcher who dedicated his life to life-saving research. May he rest in peace.

SOURCE

https://x.com/WeizmannScience/status/1941025021343797452

Weizmann Institute of Science

A Tribute to Dr. Zelig Eshhar: A Founding Father of CAR T and a Pioneer of Medical Independence

Arie Belldegrun, MD   • 2ndVerified • 2ndCo-Founder, Bellco Capital Co Chairman, Breakthrough Properties Co-Founder & Sr. Managing Partner, Vida Ventures Executive Chairman & Co-Founder, Allogene Therapeutics Co-Chairman, Symbiotic CapitalCo-Founder, Bellco Capital Co Chairman, Breakthrough Properties Co-Founder & Sr. Managing Partner, Vida Ventures Executive Chairman & Co-Founder, Allogene Therapeutics Co-Chairman, Symbiotic Capital

This Fourth of July weekend, a time when freedom and new beginnings are celebrated, we mourn the loss of one of science’s great liberators, Dr. Zelig Eshhar. His passing is deeply personal to me and profoundly impactful for the field of cancer immunotherapy.

Zelig was more than a scientist. He was a visionary who redefined what was possible in cancer treatment. As the “father” of CAR T therapy, he broke the bounds of conventional oncology and empowered the immune system to do what it was always meant to do: fight cancer. His pioneering work on chimeric antigen receptors, which began at the Weizmann Institute of Science in Israel and continued at the National Cancer Institute (NCI) at the The National Institutes of Health under another cancer legend, Dr. Steve Rosenberg, M.D., Ph.D., sparked a revolution that now brings hope to thousands of patients worldwide.

In December 2013, Kite Pharma licensed the groundbreaking CAR constructs Zelig had pioneered, forming the scientific backbone of our mission. His trust in our team was instrumental in building Kite, and he served on our Scientific Advisory Board with the humility and wisdom of a true giant. I will never forget when Zelig signed his agreement with Kite and inscribed a 50-shekel note in front of Ran Nussbaum, a fellow board member, and I, to mark “a new beginning” for CAR T therapy. Though small in size, that note carries monumental symbolic value – a belief in a better future.

One of my most cherished photographs is from 2013, standing with Dr. Zelig Eshhar and Dr. Rosenberg, two visionaries who helped launch a new chapter in medicine. That image captures more than a historic moment; it marks the start of a true paradigm shift. I knew I was among giants, but I didn’t yet grasp how life-changing that moment would be. It was Zelig who first showed us how to combine the precision of antibodies with the power of T cells, creating a therapeutic approach that would redefine what’s possible, not just in oncology, but across the spectrum of disease.

The Fourth of July celebrates independence. How fitting that we remember Zelig on this day, a man who gave medicine its own independence from the limitations of traditional cancer therapies. His legacy is not just in the patents he held or the publications he authored, but in every patient who now lives longer, stronger, and freer because of CAR T cell therapy.

To me, Zelig Eshhar will always be remembered not only as a pioneering scientist but also as a quiet hero, a generous mentor, and a dear friend. We honor him not just with words, but with action, by continuing to build, to innovate, and to carry forward the mission he began.

Zelig, your vision endures in every cell, every cure, and every life saved.

Arie Belldegrun, M.D.

SOURCE – Text & pictures

https://www.linkedin.com/posts/arie-belldegrun-md-09b32b40_a-tribute-to-dr-zeligeshhar-a-founding-ugcPost-7347296758856675328-_fUV/?utm_medium=ios_app&rcm=ACoAAAABVi0BmYKOKsh70AIfmMVAHFSJ31jS2iY&utm_source=social_share_send&utm_campaign=share_via

Prof. Selig Ashchar – one of the fathers of immunotherapy research in Israel – has passed away

Israel Prize laureate Prof. Zelig Ashchar, who was head of immunology research at Ichilov, has died at the age of 84. “My real prize is saving lives,” Ashchar said before receiving the Israel Prize 10 years ago. Ichilov Hospital paid tribute: “Beyond his unprecedented scientific achievements, Prof. Ashchar was a guide, mentor and an extraordinary human being – dedicated to his students, his colleagues and to science.”

Yaron Druckman , Oren Reis, Or Hadar |04.07.25 | 02:08

Israel Prize laureate, Prof. Selig Ashchar of the Weizmann Institute of Science, who was head of immunological research at Ichilov Hospital and a pioneer in immunotherapy research for cancer treatment, passed away at the age of 84. He is survived by three children and grandchildren

Ichilov Hospital paid tribute to him: “It is with deep sadness that we at Ichilov Hospital say goodbye to the late Prof. Selig Ashchar – a groundbreaking scientist, Israel Prize laureate, and the one who served as the head of immunological research at Ichilov. Prof. Ashchar was one of the fathers of CAR-T therapy, a real revolution in the field of cancer research, which gave new hope and life to countless patients around the world. Thanks to him, Israel became a world leader in the field of immunotherapy, and patients who had no hope – were given a new chance.”

Prof. Zelig Ashchar upon receiving the Israel Prize in 2015

( Photo: Gil Yohanan )

Ichilov also said that “Beyond his unprecedented scientific achievements, Prof. Ashhar was a guide, mentor, and an extraordinary human being – dedicated to his students, his colleagues, and to science. His spirit and legacy will continue to inspire generations of researchers and therapists. We send our deepest condolences to his family, his loved ones, and all his partners in scientific and clinical endeavors. May his memory be blessed – and a light for the path of those who seek to change the world through science and medicine.”

Dr. Anat Gloverson Levin, principal investigator of the Laboratory for Immunology and Advanced Cellular Therapy using CAR-T at Ichilov, began her doctorate at the Weizmann Institute in 2006 under the supervision of Prof. Ashchar. In a post on the social network LinkedIn, she wrote: “I share with you my deep sorrow at the death of my legendary mentor, Prof. Selig Ashchar. Selig was not only a groundbreaking scientist whose invention saved many lives, but also an extraordinary, caring, generous, and endlessly inspiring human being.”

“I had the privilege of learning from him, witnessing his passion for discovery, and being guided by his wisdom and creativity. His ideas were always ahead of their time, and his dedication to science and his students was unparalleled. I have so many wonderful memories of our time together,” she added.

Prof. Zelig Ashhar was Professor Emeritus in the Department of Immunology at the Weizmann Institute of Science, and a recipient of the 2015 Israel Prize in Life Sciences. Ashhar was an expert in the genetic engineering of T cells, and was among those who laid the foundations for the clinical application of CAR-T technology that works against cancer cells. In 2021, he also won the Dan David Prize for his groundbreaking research that led to the development of dozens of medical treatments based on the revolution he led in editing T cells to attack cancerous tumors, and for laying the foundations, together with Dr. Steven Rosenberg, for the clinical application of this technology to fight cancer.

SOURCE – Text & picture

https://www.ynet.co.il/health/article/sjmkakssxg?utm_source=ynet.app.ios&utm_term=sjmkakssxg&utm_campaign=general_share&utm_medium=social&utm_content=Header

We, @PharmaceuticalIntelligence.com published several articles involving Dr. Zelig Eshhar research:

  • Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/

  • Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as Chief Executive Officer and Arie Belldegrun, PhD (ex-Kite Therapeutics) on R&D

Curator & Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/10/15/biomolecular-condensates-a-new-approach-to-biology-originated-mit-drug-discovery-at-dewpoint-therapeutics-cambridge-ma-gets-new-leaders-ameet-nathwani-as-chief-executive-officer-and-arie-bellde/

  • Pioneers of Cancer Cell Therapy:  Turbocharging the Immune System to Battle Cancer Cells — Success in Hematological Cancers vs. Solid Tumors

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/08/19/pioneers-of-cancer-cell-therapy-turbocharging-the-immune-system-to-battle-cancer-cells-success-in-hematological-cancers-vs-solid-tumors/

  • Steroids, Inflammation, and CAR-T Therapy

Reporter: Stephen J. Williams, Ph.D.

Updated: 08/31/2020 (CRISPR edited CAR-T clinical trials)

https://pharmaceuticalintelligence.com/2015/09/14/steroids-inflammation-and-car-t-therapy/

Read Full Post »

Immuno-Timebombs: The Hidden Drivers of Age-Related Illness

Curator: Dr. Sudipta Saha, Ph. D.

 

There are two converging biological processes that drive most age-related diseases: immunosenescence and inflammaging. Together, they explain how a deteriorating immune system and chronic low-grade inflammation contribute to neurodegenerative diseases, cancer, cardiovascular disorders, and frailty.

Immunosenescence refers to the waning competence of both innate and adaptive immune systems. With age, T and B cells become less effective, and macrophage function declines. This makes older individuals more susceptible to infections and less efficient at clearing dysfunctional cells.

Inflammaging, on the other hand, is the persistent presence of inflammation without infection. Factors like gut microbiome alterations, senescent cell accumulation, and epigenetic drift contribute to this condition. Over time, this “silent fire” damages tissues and lays the groundwork for disease.

These drivers don’t just correlate with disease—they often precede it. This positions inflammaging and immunosenescence as targets for prevention, not just treatment. Interventions like exercise, caloric modulation, and anti-inflammatory diets may attenuate their effects. Emerging therapies such as senolytics and immune rejuvenation approaches (e.g., thymic regeneration) are showing promise.

This article also calls for a paradigm shift in medical science—from reactive disease management to proactive longevity interventions. As we unravel the biological clocks of aging, strategies targeting immune recalibration may delay or prevent multiple diseases simultaneously.

The future of healthy aging may well depend on how early we can intervene in this immuno-inflammatory loop—before pathology sets in.

References:

https://erictopol.substack.com/p/the-drivers-of-age-related-diseases

https://www.nature.com/articles/s41591-019-0661-0

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761661

https://www.cell.com/fulltext/S0092-8674(19)30184-4

https://www.frontiersin.org/articles/10.3389/fimmu.2020.579220/full

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649506

Read Full Post »

Sleeping Threats: Immune System’s Watch on Dormant Cancer

Curator: Dr. Sudipta Saha, Ph. D.

 

The immune system’s role in regulating dormant cancer cells has been increasingly elucidated, revealing a complex interplay that influences metastasis and cancer recurrence. Dormant cells, which enter a non-proliferative state, can evade immune detection and remain quiescent for prolonged periods.


Mechanisms of immune evasion include down-regulation of antigen presentation and residence within immune-privileged niches such as bone marrow. Both innate and adaptive immunity, particularly CD8+ T cells and natural killer cells, are involved in maintaining dormancy and preventing metastatic outgrowth.


Micro-environmental factors that modulate immune surveillance and dormancy status have been identified. Changes in cytokine profiles and inflammation can disrupt dormancy, leading to cancer cell reactivation and metastasis.


Therapeutic approaches to sustain dormancy or eliminate dormant cells are under development. These include immune checkpoint inhibitors, cancer vaccines, and cytokine modulators aimed at enhancing immune recognition and clearance.


By targeting dormant cancer cells through immune modulation, it is anticipated that metastasis can be delayed or prevented, significantly improving long-term patient outcomes and reducing cancer mortality.

References:

https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastasis-dormant-cancer-cells-immune-system

https://www.nature.com/articles/nrc2256

https://pubmed.ncbi.nlm.nih.gov/33681821/

https://pubmed.ncbi.nlm.nih.gov/33811127/

https://www.nature.com/articles/nrc3910

https://pubmed.ncbi.nlm.nih.gov/27015306

 

Read Full Post »

Resitu Medical Sets Stage for Breakthrough in Breast Tumour Removal

Curator: Dr. Sudipta Saha, Ph.D.

Resitu Medical, a Swedish company specializing in minimally invasive breast tumour removal, has announced the appointment of Stefan Sowa as its new Chief Executive Officer. Strategic leadership is being strengthened as the company moves towards commercialization in both European and American markets.

A novel electrosurgical device, designed to excise entire breast lesions during the biopsy procedure, is being developed by Resitu. The device is intended to minimize the need for open surgery by allowing intact removal of tissue with minimal bleeding, guided by real-time ultrasound imaging. Preclinical studies are currently being conducted, and preparations for FDA clearance and CE marking are underway.

ISO 13485 certification for the design, development, manufacturing, and sales of the device has been successfully obtained. Investment has been secured from major shareholders, including Novoaim, ALMI Invest Stockholm, and STOAF, to support the finalization of the product and the initiation of serial production for clinical trials.

Through the use of its technology, false negatives are hoped to be reduced, while patient outcomes and diagnostic accuracy are expected to be significantly improved. The burden on healthcare systems may also be alleviated by minimizing the need for recalls and secondary biopsies.

Positive attention has been garnered at major medical conferences, with workshops hosted at events such as the Uppsala Breast Meeting, and favourable media coverage has been achieved. With Stefan Sowa at the helm, Resitu’s innovative device is poised to transform breast cancer management practices globally.

References

https://news.cision.com/let-em-know-ab/r/resitu-strengthens-c-suite-with-new-ceo-as-it-prepares-for-commercialization-of-its-breast-tumor-rem,c4140424

https://www.resitu.com

https://www.who.int/news-room/fact-sheets/detail/breast-cancer

Read Full Post »

SNU-BioTalk 2025: Symphony of Cellular Signals in Metabolism and Immune Response – International Conference at Sister Nivedita University, Kolkata, India on 16 & 17 January 2025

SNU-BioTalk 2025: Symphony of Cellular Signals in Metabolism and Immune Response – International Conference at Sister Nivedita University, Kolkata, India on 16 & 17 January 2025

Joint Convenor: Dr. Sudipta Saha (Member of LPBI since 2012)

About the Conference:

The International Conference on ‘Symphony of Cellular Signals in Metabolism and Immune Response’ focuses on the complex signalling pathways governing cellular functions in health and disease. It will explore the cellular mechanisms that regulate metabolism, immune responses, and survival, highlighting advances in medical science and biotechnology. Bringing together leading experts and emerging researchers, the conference will feature keynote lectures, panel discussions, research presentations, and interactive sessions, all designed to foster collaboration and innovation. By promoting an exchange of ideas, the event aims to drive transformative insights and solutions that impact human health and sustainable healthcare practices.

The conference will also be livestreamed on YouTube and Facebook

This programme will also host I-STEM: Indian Science, Technology and Engineering facilities Map (I-STEM) is a dynamic and interactive national portal for research cooperation.

Thrust areas:

  • Intracellular signalling processes of cellular metabolism
  • Signalling pathways in physiological and pathological processes
  • Signalling in innate and adaptive immunity

Conference Webpage: https://www.snuniv.ac.in/snu-biotalk-2025/

NU-BioTalk 2025 Abstract Submission Form: https://forms.gle/ygdGqtuBGa7DEhDFA

SNU-BioTalk 2025 Registration Form: https://forms.gle/unasPpByLmYwrRBM6

Programme Schedule:

YouTube Links of Live Telecast:

Day 1:

Day 2:

Media:

Newspaper:

The Telegraph – Click to View

 

Abstract Book

Scan to Download:

Click: 

Abstract Book

Read Full Post »

10th annual World Medical Innovation Forum (WMIF) Monday, Sept. 23–Wednesday, Sept. 25 at the Encore Boston Harbor in Boston

Dr. Aviva Lev-Ari, PhD, RN, Founder

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

will be in attendance

covering this event in REAL TIME for PharmaceuticalIntelligence.com and WMIF organizers

#WMIF2024

@Pharma_BI

@AVIVA1950

CLAIMER: Live coverage in REAL TIME on X.com for 9/23/2024

my two X.com accounts had exceeded tweeting volume capacity and were inactivated to verify if I am a person or a BOT. Account authentication reported SOmething went wrong, try later.

  • 9/23/2024 contacted Customer Services at X.com for reactivated these two accounts

 

For Speaker’s quotes on 9/23/2024 from 4PM EST to end on the day

  • see below on WordPress.com by Date, Time, Session Name and Speaker Name

For Speaker’s quotes on 9/24/2024 from 8AM to 5:30PM

  • see below on WordPress.com by Date, Time, Session Name and Speaker Name

For Speaker’s quotes on 9/25/2024 from 8AM to 12:35PM

  • see below on WordPress.com by Date, Time, Session Name and Speaker Name

UPDATE on reactivation of handles on X.com will be posted, here.

Usage of X.com will resume after Handle reactivation by X.com

 

UPDATED on 9/26/2024

Unmet Needs Panel

https://www.youtube.com/watch?v=e6hk7yavBzk

100+ Mass General Brigham Leading Experts Identify

Top Unmet Needs in Healthcare

Project from Harvard Medical School-affiliated clinicians and scientists in the Mass General Brigham healthcare system stimulates new consideration, urgency regarding

innovation in life sciences, healthcare

Top 10 List Announced at World Medical Innovation Forum

BOSTON, MA September 25, 2024 – Some of the most vexing challenges and transformational opportunities in healthcare are included in a new list, “Top Unmet Needs in Healthcare” released by leading experts at Mass General Brigham. Identified by more than 100 Harvard Medical School faculty at Mass General Brigham, the findings range from the need to expand and accelerate rare disease treatment, to the coming “gray tsunami” of aging patients and the implications for patient care, delivery, and technology. The project, revealed at the 10th annual World Medical Innovation Forum, is meant to stimulate new consideration and urgency regarding solving and advancing these issues for improved patient care.

Views from Leading Clinicians, Researchers, and Practitioners in Academic Medicine

The Top Unmet Needs emerge from structured one-on-one discussions with more than 100 Harvard faculty who practice medicine and conduct research at Mass General Brigham, the largest hospital system-based research enterprise in the U.S., with an annual research budget exceeding $2 billion, and five of the nation’s top hospitals according to US News & World Report.

Through one-on-one discussions with these key opinion leaders from diverse clinical and research fields, and subsequent analyses by internal teams of experts, Mass General Brigham has identified the following top 10 unmet clinical needs:

#1. Preparing for the ‘Gray Tsunami’

The need for better tools and therapies aimed at caring for geriatric populations and maintaining geriatric independence, with a particular focus on expanded hospital-at-home capabilities, and the need to better understand the pathways that lead to chronic and acute disease in geriatric patients to enable better and more proactive treatment.

#2. Defining and Maintaining Brain Health

The need for a model of brain health and neurological care that clearly defines not only what brain health is but also integrates our current understanding of the mechanisms and phases of neuroinflammatory and neurodegenerative diseases; enables better and earlier diagnoses and treatment; and propels the development of therapies that target these mechanisms and phases.

#3. A Paradigm Shift in Cancer Treatment

The need for a new framework for therapeutic development in cancer that is focused on improving curability as opposed to an exclusive focus on the development of drugs for metastatic disease. This

framework also requires effective tools for early-stage cancer detection across the board in all cancers, but especially in lung, ovarian, pancreatic, and GI cancers (esophagus, stomach and colon).

#4. Targeting Fibrosis, a Shared Culprit in Disease

The need for therapeutics that target fibrosis (tissue scarring), which is responsible for a significant percentage of deaths worldwide, representing diseases of the lung, liver, kidney, heart, and skin.

#5. New Approaches for Infectious Disease in a Changing World

The need for novel strategies for the rapid diagnoses, treatment, and even prevention of antibiotic-resistant infections, and the need for the next generation of globally deployable vaccines to enable pandemic preparedness.

#6. Striving for Equity in Healthcare

The need to radically rethink how, when, and where patients interact with healthcare services to optimize healthcare access and efficiency without diminishing its effectiveness, and to proactively meet the needs of currently underserved populations.

#7. Riding the Wave of Clinical Data

The need to expand the scope of available clinical data to include historically understudied populations (including women) and to model and implement a cohesive, dynamic data “stream,” which flows as patients do between the different phases of health and clinical care, enabling comparisons of patients to their previously healthy selves and the development of AI/ML approaches to harness these data to improve diagnosis, prognosis, and treatment.

#8. A Systems-Level View of Human Disease

The need to rethink how we understand and treat disease — not only from an organ-specific standpoint but from a whole-body, systems-level view — and to fully elucidate the roles that inflammation and immune pathways play in autoimmune and infectious diseases and their effects on chronic and acute diseases in diverse human systems, such as the cardiovascular/circulatory and nervous systems.

#9. A New Approach to Psychiatric Disease

The need for novel treatments for psychiatric disease, improved biomarkers and minimally invasive and ambulatory ways of measuring them, and more productive interactions with industry to advance new therapies to the clinic. This includes hybrid therapies (therapies that combine elements such as talk therapy, novel biomarkers, and pharmacological treatments) as well as new diagnostic and treatment modalities, such as psychedelic therapeutics and precision psychiatry.

#10. Charting a Course in Rare Disease Treatment

The need for viable treatments for the 7,000 identified rare diseases, especially the roughly 70% of such diseases that are genetic and the effects of which are first observed in early childhood.

The Unmet Needs list also include the following honorable mentions which rose to significant rankings in the analysis:

  • Driving Innovation in Chronic Disease: Improved Diagnosis, Treatment, and Prevention
  • A New Era of Obesity Medicine
  • A New Generation of Pain Treatments
  • Unlocking Novel Treatments for the Skin

Overarching Themes

Addressing unmet clinical needs involves solving a number of common challenges, including commercialization hurdles, regulatory considerations, and funding. The Mass General Brigham project identified overarching themes to help address these challenges and support innovation across multiple sectors. These include:

  • Taking a systems view of human disease and the practice of system-medicine
  • Developing a global view of infectious disease, including antimicrobial resistance
  • An expansion in high-quality, real-world data that closes gaps in current data (particularly for women and other underserved populations) and ensures that data sets are sufficiently enabling for AI/ML
  • Improving health and healthcare across key populations, including geriatrics and rare genetic disease
  • Addressing major diseases of the brain, including both neurodegenerative and neuropsychiatric conditions; these include Alzheimer’s disease, Parkinson’s disease, ALS, as well as psychiatric and mental health disorders
  • Opening an era of precision medicine across disease areas that includes early diagnosis, treating staged disease, and biomarker discovery and utilization

Panel co-chairs José Florez, Physician-in-Chief and Co-Chair of the MGB Department of Medicine and the Jackson Professor of Clinical Medicine at Harvard Medical School, and Bruce Levy, Physician-In-Chief and Co-Chair of the MGB Department of Medicine and the Parker B. Francis Professor of Medicine at Harvard Medical School, noted how the observations of a broad and representative set of faculty help illuminate the innovation landscape ahead.

“As a leader in patient care and healthcare innovation, our goal is to build on the legacy of research and discovery that has shaped the hospitals of the Mass General Brigham healthcare system for more than a hundred years, and continue to bring breakthroughs forward that can help solve pressing needs,” said Dr. Florez.

Dr. Levy added that “This is a roadmap for the future that can inform discussions happening throughout the healthcare and investment ecosystem regarding the future of medicine.”

More than 2000 decision-makers from healthcare, industry, finance and government attended the World Medical Innovation Forum this week in Boston. A premier global event, the Forum highlights leading innovations in medicine and transformative advancements in patient care.

###

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

Contact: Tracy Doyle Mass General Brigham Innovation

(262) 227-5514

Tdoyle5@mgb.org

SOURCE

From: “Doyle, Tracy” <tdoyle5@mgb.org>
Date: Thursday, September 26, 2024 at 10:19 AM
Cc: “Card, Matthew” <matthew.card@bofa.com>
Subject: Unmet Needs in Healthcare — Press Release and link to panel

 

@@@@@@@

Invitation as MEDIA

From: “Doyle, Tracy” <tdoyle5@mgb.org>
Date: Wednesday, August 14, 2024 at 4:04 PM
Cc: “Doyle, Tracy” <tdoyle5@mgb.org>, “Card, Matthew” <matthew.card@bofa.com>
Subject: Media Invite: World Medical Innovation Forum, Sept. 23-25, Boston — Hundreds of clinical experts, industry, investment leaders

 

Media Invite: World Medical Innovation Forum: Monday, Sept. 23—Wednesday, Sept. 25, Boston

At the intersection of innovation and investment in healthcare

Join Us!

Register Now: WMIF24 Media Registration

Mass General Brigham, one of the nation’s leading academic medical centers, is pleased to invite reporters to the 10th annual World Medical Innovation Forum (WMIF) Monday, Sept. 23–Wednesday, Sept. 25 at the Encore Boston Harbor in Boston. The event features expert discussions of scientific and investment trends for some of the hottest areas in healthcare, including

  • GLP-1s,
  • the cancer care revolution,
  • generative AI-enabled care paths,
  • xenotransplant,
  • community health,
  • hospital at home, and
  • therapeutic psychedelics, among many others.

 

The agenda includes nearly 175 executive speakers from healthcare, pharma, venture, start-ups, and the front lines of care, including many of Mass General Brigham’s Harvard Medical School-affiliated researchers and clinicians who this year will host 20+ focused sessions. Bank of America, presenting sponsor of the Forum, will provide additional expert insights on the investment landscape associated with healthcare innovation.

 

Forum highlights include:

 

1:1 and panel interviews with leading CEOs and government officials including:

  • Stéphane Bancel, CEO, Moderna
  • Albert Bourla, PhD, CEO, Pfizer
  • Marc Casper, CEO, Thermo Fisher
  • Deepak Chopra, MD, Founder, The Chopra Foundation
  • Scott Gottlieb, MD, PhD, Former Commissioner, FDA (2017-2019)
  • Maura Healey, Governor, Commonwealth of Massachusetts
  • David Hyman, MD, CMO, Eli Lilly
  • Haim Israel, Head of Global Thematic Investing Research, BofA Global Research
  • Reshma Kewalramani, MD, CEO, Vertex
  • Anne Klibanski, MD, President and CEO, Mass General Brigham
  • Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA
  • Tadaaki Taniguchi, MD, PhD, Chief Medical Officer, Astellas Pharma
  • Christophe Weber, CEO, Takeda
  • Renee Wegrzyn, PhD, Director, ARPA-H

 

Expert panels including:

  • Oncology’s New Paradigm
  • Gene Therapies for Rare Diseases
  • Future of Metabolic Therapies
  • Digital Transformation
  • Biologic Revolution in Radiotherapies
  • Cell Therapies for Autoimmune Diseases
  • Hospital Venture Funds

 

Leading biotech and venture speakers from companies including:

  • Abata Therapeutics
  • Atlas Venture
  • Be Biopharma
  • Everly Health
  • Flagship Pioneering
  • Fractyl Health
  • MindMed
  • Mirador Therapeutics
  • Regor Therapeutics
  • RH Capital
  • Transcend Therapeutics


Exclusive programming:  

  • First Look – 15 rapid-fire presentations on the latest research from leading Mass General Brigham scientists
  • Un-Met Clinical Needs – 100+ key opinion leaders in healthcare weigh in on the top un-met clinical needs in medicine today
  • Emerging Tech Zone – Hands-on exploration of some of the latest digital and AI-based healthcare technologies

 

Our program keeps growing — explore the current Forum agenda and list of speakers.

FORUM AGENDA

SOURCE

https://2024.worldmedicalinnovation.org/agenda/

Monday, September 23, 2024

    • 7:00 AM – 8:30 AM

      Picasso Foyer

    • 7:00 AM – 5:00 PM

      Rotunda

    • 8:00 AM – 10:00 AM

      Picasso Ballroom

      First Look

      First Look: 14 rapid fire presentations

      Moderators

      Giles Boland, MD

      President, Brigham and Women’s Hospital and Brigham and Women’s Physicians Organization;

      Philip H. Cook Distinguished Professor of Radiology, Harvard Medical School

      Marcela del Carmen, MD

      President, Massachusetts General Hospital and Massachusetts General Physicians Organization (MGPO);

      Executive Vice President, Mass General Brigham;

      Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

      Presenters

      Natalie Artzi, PhD

      Associate Professor of Medicine, Brigham and Women’s Hospital & Harvard Medical School

      Yolonda Colson, MD, PhD

      Chief, Division of Thoracic Surgery, Massachusetts General Hospital;

      Hermes C. Grillo Professor of Surgery, Harvard Medical School

      Nobuhiko Hata, PhD

      Director, Surgical Navigation and Robotics Laboratory, Brigham and Women’s Hospital;

      Professor of Radiology, Harvard Medical School

      John Hanna, MD, PhD

      Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

      Leigh Hochberg, MD, PhD

      Director of Neurotechnology and Neurorecovery, Massachusetts General Hospital;

      Senior Lecturer on Neurology, Harvard Medical School

      Daphne Holt, MD, PhD

      Director of the Resilience and Prevention Program, Massachusetts General Hospital;

      Associate Professor of Psychiatry, Harvard Medical School

      Ole Isacson, MD-PhD

      Founding Director, Neuroregeneration Research Institute, McLean Hospital;

      Professor of Neurology and Neuroscience, Harvard Medical School

      Farouc Jaffer, MD, PhD

      Director, Coronary Intervention, Massachusetts General Hospital;

      Associate Professor of Medicine, Harvard Medical School

      Albert Kim, MD

      Assistant Physician, Mass General Cancer Center;

      Assistant Professor, Harvard Medical School

      Vesela Kovacheva, MD, PhD

      Director of Translational and Clinical Research, Mass General Brigham;

      Assistant Professor of Anesthesia, Harvard Medical School

      Mark Poznansky, MD, PhD

      Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital;

      Steve and Deborah Gorlin MGH Research Scholar;

      Professor of Medicine, Harvard Medical School

      Daniel Solomon, MD

      Matthew H. Liang Distinguished Chair in Arthritis and Population Health, Brigham and Women’s Hospital;

      Professor of Medicine, Harvard Medical School

      Scott Solomon, MD

      Director, Clinical Trials Outcomes Center;

      Edward D. Frohlich Distinguished Chair in Cardiovascular Pathophysiology, Brigham and Women’s Hospital;

      Professor of Medicine, Harvard Medical School

      Guillermo Tearney, MD, PhD

      Principal Investigator, Wellman Center for Photomedicine, Massachusetts General Hospital;

      Remondi Family Endowed MGH Research Institute Chair;

      Professor of Pathology, Harvard Medical School

      Raul Uppot, MD

      Interventional Radiologist, Massachusetts General Hospital;

      Associate Professor, Harvard Medical School

      David Walt, PhD

      Professor of Pathology, Brigham and Women’s Hospital;

      Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School

    • 10:00 AM – 10:20 AM

    • 10:20 AM – 10:30 AM

    • 10:30 AM – 10:55 AM

      Fireside

      Fireside Chat

      Moderator

      Keith Flaherty, MD

      Director of Clinical Research, Mass General Cancer Center;

      Professor of Medicine, Harvard Medical School

      Panelist

      Albert Bourla, PhD

      Chairman & CEO, Pfizer

    • 11:00 AM – 11:45 AM

Concurrent Events

  • 11:00 AM – 11:45 AM

    Oncology’s New Paradigm

    Moderators

    Keith Flaherty, MD

    Director of Clinical Research, Mass General Cancer Center;

    Professor of Medicine, Harvard Medical School

    Jason Zemansky, PhD

    SMid-Cap Biotech Analyst, BofA Global Research

    Panelists

    Jonathan Carlson, MD, PhD

    Director of Chemistry, Center for Systems Biology, Massachusetts General Hospital;

    Assistant Professor of Medicine, Harvard Medical School

    Gad Getz, PhD

    Director of Bioinformatics, Krantz Center for Cancer Research and Department of Pathology;

    Paul C. Zamecnik Chair in Cancer Research, Mass General Cancer Center;

    Professor of Pathology, Harvard Medical School

    Russell Jenkins, MD, PhD

    Krantz Family Center for Cancer Research, Massachusetts General Hospital;

    Mass General Cancer Center, Center for Melanoma;

    Assistant Professor of Medicine, Harvard Medical School

    Gregory Simon

    President, Simonovation

    Shannon Stott, PhD

    Associate Investigator, Krantz Family Center for Cancer Research and Mass General Cancer Center;

    d’Arbeloff Research Scholar, Massachusetts General Hospital;

    Associate Investigator, Krantz Family Center for Cancer Research Harvard Medical School

  • 11:00 AM – 11:45 AM

    GLP-1s: How Far Will They Go?

    Moderators

    Tazeen Ahmad

    SMid-Cap Biotech Analyst, BofA Global Research

    Fatima Cody Stanford, MD

    Obesity Medicine Physician Scientist, Massachusetts General Hospital;

    Associate Professor of Medicine and Pediatrics, Harvard Medical School

    Panelists

    Caroline Apovian, MD

    Co-Director, Center for Weight Management and Wellness, Brigham and Women’s Hospital;

    Professor of Medicine, Harvard Medical School

    Vanita Aroda, MD

    Director, Diabetes Clinical Research, Brigham and Women’s Hospital;

    Associate Professor, Harvard Medical School

    Paul LaViolette

    Managing Partner & COO, SV Health Investors

  • 11:00 AM – 11:45 AM

    Generative AI: Breakthrough Research and Limitations

    Moderators

    Adam Landman, MD

    Chief Information Officer & SVP, Digital, Mass General Brigham;

    Associate Professor of Emergency Medicine, Harvard Medical School

    Alec Stranahan, PhD

    SMid-Cap Biotech Analyst, BofA Global Research

    Panelists

    Katherine Andriole, PhD

    Director of Academic Research and Education, Mass General Brigham Data Science Office;

    Associate Professor, Harvard Medical School

    David Blumenthal, MD

    Professor of Practice of Public Health and Health Policy, Harvard TH Chan School of Public Health;

    Research Fellow, Harvard Kennedy School of Government;

    Samuel O. Thier Professor of Medicine, Emeritus, Harvard Medical School

    Faisal Mahmood, PhD

    Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

    William Morris, MD

    Chief Medical Information Officer, Google Cloud

  • 11:00 AM – 11:45 AM

    Gene and Cell Therapy’s Unlimited Potential

    Moderators

    Roger Hajjar, MD

    Director, Gene & Cell Therapy Institute, Mass General Brigham

    Charlie Yang, PhD

    Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

    Nathan Yozwiak, PhD

    Head of Research, Gene and Cell Therapy Institute, Mass General Brigham

    Panelists

    Samarth Kulkarni, PhD

    CEO, CRISPR Therapeutics

    Peter Marks, MD, PhD

    Director, Center for Biologics Evaluation and Research, FDA

    Marcela Maus, MD, PhD

    Director of Cellular Therapy and Paula O’Keeffe Chair in Cancer Research, Krantz Family Center for Cancer Research and Mass General Cancer Center;

    Associate Director, Gene and Cell Therapy Institute, Mass General Brigham;

    Associate Professor, Harvard Medical School

    Joanne Smith-Farrell, PhD

    CEO & Director, Be Biopharma

  • 11:00 AM – 11:45 AM

    Xenotransplant: Game Changing Organ Replacement

    Moderators

    Jason Gerberry

    Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

    Joren Madsen, MD, PhD

    Director, MGH Transplant Center;

    Paul S. Russell/Warner-Lambert Professor of Surgery, Harvard Medical School

    Panelists

    Tatsuo Kawai, MD, PhD

    Director of the Legorreta Center for Clinical Transplantation Tolerance,

    A.Benedict Cosimi Chair in Transplant Surgery, Massachusetts General Hospital;

    Professor of Surgery, Harvard Medical School

    Richard Pierson III, MD

    Scientific Director, Center for Transplantation Sciences, Massachusetts General Hospital;

    Professor of Surgery, Harvard Medical School

    Leonardo Riella, MD, PhD

    Medical Director of Kidney Transplantation, Massachusetts General Hospital;

    Harold and Ellen Danser Endowed Chair in Transplantation, Harvard Medical School

Concurrent Events

  • 12:00 PM – 12:45 PM

    Future of Cancer Care

    Moderator

    Alec Stranahan, PhD

    SMid-Cap Biotech Analyst, BofA Global Research

    Panelists

    Gerard Doherty, MD

    Surgeon-in-Chief, Mass General Brigham Cancer;

    Surgeon-in-Chief, Brigham and Women’s Hospital;

    Moseley Professor of Surgery, Harvard Medical School

    Daphne Haas-Kogan, MD

    Chief, Enterprise Radiation Oncology, Mass General Brigham;

    Professor, Harvard Medical School

    Benjamin Kann, MD

    Assistant Professor, Brigham and Women’s Hospital & Harvard Medical School

    David Ryan, MD

    Physician-in-Chief, Mass General Brigham Cancer;

    Professor of Medicine, Harvard Medical School

  • 12:00 PM – 12:45 PM

    Generative AI Enabled Care Paths

    Moderators

    Adam Ron

    Health Care Facilities and Managed Care Analyst, BofA Global Research

    Marc Succi, MD

    Executive Director, Mass General Brigham MESH Incubator;

    Associate Chair of Innovation & Commercialization, Mass General Brigham Radiology;

    Assistant Professor, Harvard Medical School

    Panelists

    Christopher Longhurst, MD

    Chief Medical & Digital Officer, UC San Diego Health

    Rebecca Mishuris, MD

    Chief Medical Information Officer, Mass General Brigham;

    Member of the Faculty, Harvard Medical School

    Shiv Rao, MD

    CEO & Founder, Abridge

    Alkesh Shah

    Head of US Equity Software Research, BofA Global Research

  • 12:00 PM – 12:45 PM

    Transforming Care in a Resource Limited Era

    Moderator

    Niyum Gandhi

    CFO & Treasurer, Mass General Brigham

    Panelists

    Fritz François, MD

    Executive Vice President and Vice Dean, Chief of Hospital Operations, NYU Langone Health

    Susan Huang, MD

    EVP, Chief Executive, Providence Clinical Network, Providence Southern CA

    Ron Walls, MD

    Chief Operating Officer, Mass General Brigham;

    Neskey Family Professor of Emergency Medicine, Harvard Medical School

  • 12:00 PM – 12:45 PM

    Cardiovascular Pipeline Renewal

    Moderators

    Jason Gerberry

    Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

    Calum MacRae, MD, PhD

    Vice Chair for Scientific Innovation, Department of Medicine, Brigham and Women’s Hospital;

    Professor of Medicine, Harvard Medical School

    Panelists

    Lotte Bjerre Knudsen, DMSc

    Chief Scientific Advisor, Novo Nordisk

    David Grayzel, MD

    Partner, Atlas Venture

    Christoph Westphal, MD, PhD

    General Partner, Longwood Fund

    Deborah Wexler, MD

    Chief, Diabetes Unit, Massachusetts General Hospital;

    Associate Professor of Medicine, Harvard Medical School

  • 12:45 PM – 1:00 PM

  • 1:00 PM – 1:20 PM

    Picasso Ballroom

    Opening Remarks

    Introducer

    Miceal Chamberlain

    President of Massachusetts, Bank of America

    Opening Remarks

    Maura Healey

    Governor of the Commonwealth of Massachusetts

  • 1:20 PM – 2:00 PM

    Picasso Ballroom

    Healthcare Innovation and Regional Competitiveness

    Panelists

    John Fish

    Chairman & CEO, Suffolk

    Reshma Kewalramani, MD

    CEO & President, Vertex Pharmaceuticals

    Jonathan Kraft

    President, The Kraft Group;

    Board Chair, Massachusetts General Hospital

  • 2:05 PM – 2:30 PM

    Picasso Ballroom

    Fireside

    Fireside Chat

    Moderators

    Tazeen Ahmad

    SMid-Cap Biotech Analyst, BofA Global Research

    Roger Hajjar, MD

    Director, Gene & Cell Therapy Institute, Mass General Brigham

    Panelist

    Reshma Kewalramani, MD

    CEO & President, Vertex Pharmaceuticals

  • 2:35 PM – 3:10 PM

    Picasso Ballroom

    Delivering Care: New Tools, Evolving Challenges, Bold Aspirations

    Moderator

    Andrew Bressler

    Washington Healthcare Policy Analyst, BofA Global Research

    Panelists

    Rod Hochman, MD

    President & CEO, Providence

    Anne Klibanski, MD

    President & CEO, Mass General Brigham;

    Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

    Kevin Mahoney

    CEO, University of Pennsylvania Health System

  • 3:10 PM – 3:35 PM

    Picasso Ballroom

    Fireside

    Fireside Chat

    Moderators

    Caroline Sokol, MD, PhD

    Assistant Physician, Massachusetts General Hospital;

    Assistant Professor, Harvard Medical School

    Charlie Yang, PhD

    Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

    Panelist

    Mark McKenna

    Chairman & CEO, Mirador Therapeutics

3:40 PM – 4:05 PM

Picasso Ballroom

RECORDING OF SPEAKERS’ QUOTES ON WordPress.com
 
STARTS HERE

Fireside

Fireside Chat

Moderators

Jason Gerberry

Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

Allan Goldstein, MD

Chief of Pediatric Surgery, Massachusetts General Hospital;

Surgeon-in-Chief, Mass General for Children;

Marshall K. Bartlett Professor of Surgery, Harvard Medical School

Panelist

Christophe Weber, President & CEO, Takeda

  • pipeline is very diverse at the R&D center in Boston

Phase III:

  • TAK-279 Psorisis
  • Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study

The Markets for Takeda

  • US market is 40% of revenue, It is a difficult market but still the most important for Phama in the World
  • Japan is 8%
  • Growth by acquisitions and internal development like above, two Phase III drugs

Price control and policies:

  • negotiation
  • price war create tension

Team:

Public company traded in NYSE

  • Management team has 10 nationalities – Global company
  • AI is adopted as a digital companion

Recruiting Patients for Clinical Trial:

  • Very difficult

M&A

  • After acquisition of Shire – not many other opportunities are left

4:05 PM – 4:40 PM

Picasso Ballroom

The Innovation Gap: A Review of the Future of Viral Vector Manufacturing and the Delivery of Genetic Medicines

Moderators

Elizabeth Henske, MD, Director, Center for LAM Research and Clinical Care, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Panelists

Peter Anastasiou, CEO, Capsida Biotherapeutics

  • Capsid technology for Liver disease, Parkinson’s
  • AV and CNS crossing BBB
  • One capsid for one disease
  • manufacture caspids
  • Challenges:  manufacturable after screening
  • IV delivery – brain disorder, blood flow would bring therapeutics to all brain tissue consistently vs localized
  • Partnership with Eli Lilly and with Crisper technologies with Abbvie

Steve Favaloro, Chairman & CEO, Genezen

  • 200 persons Team manufacture
  • Partnerships: synthetic plasma

Alexandria Forbes, PhD, CEO, MeiraGTx

  • Optimize promoters, control transcription expression by injection or by pill, control translation
  • improving potency of gene therapies capsule technology
  • cost hundred of $ not thousand of $
  • ALL manufacturing in house
  • 9 years of data can help to narrow down the parameters
  • time frame is shortened
  • company established 9 years ago
  • apply DNA expression – invented a technology
  • splicing control mRNA
  • control cell lines
  • give an injection or a pill and control antibodies, glucagon
  • control dosing for efficatious therapeutics
  • Potency
  • Ribozon is a delivery system
  • Partnership with J&J –

Fraser Wright, PhD, Chief Gene Therapy Officer, Kriya Therapeutics

  • manufacturing – changing in capsule design
  • manufacture viruses
  • cost of manufacturing – efficiency matters a lot
  • delivery of the gene in the tissue
  • Partnerships: basic vs applied Quality from research to manufacturing

4:45 PM – 5:20 PM

Picasso Ballroom

A Deep Dive on Genetic Modalities for Rare Disease: Genetic Medicines Are Here

Moderator

Tazeen Ahmad, SMid-Cap Biotech Analyst, BofA Global Research

  • Treat once or repeat therapy?

Patricia Musolino, MD, PhD, MGH

 

Panelists

Faraz Ali, Tenaya Therpeutics

  • genetic therapy for a genetic mutation – NOVEL approach
  • 400 mutation related to cardiomyopathy
  • 2018 – gene therapy was an innovation
  • genetic medicine Cardiology introducing opportunities wiht validation that did not exist
  • find novel targets Partnerships are a must to have
  • Viral therapies vs gene therapy

Lucas Harrington, PhD, Co-Founder & CSO, Mammoth Biosciences

  • How to turm Genome 2012 to therapy?
  • targeting: Taking risk Patient interaction with treatment
  • variation between Rare diseases some are very small some are not small – incentive to investors
  • The field will grow fast

Raju Prasad, PhD, Chief Financial Officer, CRISPR Therapeutics

  • various indications
  • FDA Approval
  • Gene editing technology for rare diseases
  • LPA for RNA therapy
  • incentive to investors
  • Important for investor to understand the siize of the market, CRISPR can be a technology for a large market size
  • Sickle cell disease – market is large and therapy can be made affordable

 

Sandi See Tai, MD, Chief Development Officer, Lexeo Therapeutics

  • cardiomyopathy
  • protective gene
  • Early genetic testing
  • Educating patients

5:20 PM – 6:30 PM

Picasso Terrace and Harborside Lawns 1 & 2

Tuesday, September 24, 2024

8:00 AM – 8:55 AM

Picasso Ballroom

The Transforming World

Introducer

Liz Everett Krisberg, Head of Bank of America Institute

  • Record attendance this year
  • Introduction to Haim

Panelist

Haim Israel

Head of Global Thematic Investing Research, BofA Global Research

  • Concept of the Future and for the Future: Short-term and long-term
  • Humanity achievements in Ten Year: Data, Processing power and BRAIN – Long-term becomes Short-term – Last 10 years: 2012, 2014 solar system, 2015 medicine, 2019 blackhole, 2023 core of sun – star was created hotter than core sun
  • 2022, 2024 – galaxy picture of the universe
  • Volume of data created every month in terrabyts every 18 month data is duplicating itself.
  • Olny 1% is used – imagine 2% or 3%
  • Processing power since Apollo 11 [one trillion] – getting cheaper – cost for calculation went down 16,000 fold since 1995
  • AMMOUNT of DATA goes up and Cost of COMPUTATION goes down – price per giga byte
  • Projections for the next 100 years
  • Negative for people and Negative for Companies who are concerned with quarterly financial data
  • Companies: Walmart, Alphabet, Home Depot – DATA larger that COuntries
  • Living in defining moment: started by iPhone revolution and 2023 by AI revolution – 6x outpaced Moore’s Law by GPT by 3000x
  • 18 months into AI revolution – GPT in use
  • The next 10 years:
  1. Aging population
  2. 2024 – birth rate low in US, Japan, CHina, S. Korea – Pension system will decline in size
  3. 2.2 millions new material were created by DeepMind at Alphabet by simulation of AI on molecule
  4. Microsoft in 80 hours identified 18 materials winners for Batteries using AI from 32 million material candidates
  5. AI- weather calculations in minutes 1,000x faster, cheaper and more accurate
  6. 2025 – GPT-6 AI surpass Human Brain
  7. China is a big player in AI
  8. Cyber CRIME is the 3rd largest economy in the World. Hackers are using ChatGPT to create fake pictures leading to ZERO privacy
  • PRIVACY: Deepfakes up 62x, social media
  • 2024 – Global Grid – needs much more energy because AI consumes so much energy
  • Metals shortages: Nickel, Copper,
  • Scarcity of water for 2/3 of the planet
  • data centers consume water more than Japan
  • 2025 – Genomics Data sequencing bigger that X.com or Youtube
  • 2027 – Peak oil demand: needed to be scalable, cheaper 25%
  • 2028 – 5G networks reaches full capacity, 6G will be needed
  • 2029 – 25x more satellites in Orbit than today
  • 2029 – Personalized AI medicines and treatments will manipulate death and revive LONGEVITY – AI will generate drugs and all treatments
  • 2030Generative AI:  re-skill 1 Billion people
  • 2035 – Fusion energy, known technology since the atomic bomb, how to keep it stable in plasma state of material – not yet achieved, it is clean, cheap: to Power the World – equivalent of 11 barrels of oil
  • Large cities: Cable diameter 17cm wide to power a large city
  • AI will change scarcity into abundance
  • 2037 – Artifitial SUPER Intelligence – AI to outsmart Life
  • Quantum computer – Consortium of NASA and other governmental agencies and Google on quantum computer design
  • 2024 the most interesting year in human history

 

Concurrent Events

  • 9:00 AM – 9:45 AM

    Current and Future States of Immunology

    Moderators

    Caroline Sokol, MD, PhD, Assistant Physician, Massachusetts General Hospital;, Assistant Professor, Harvard Medical School

    Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

    Panelists

    Dong Feng Chen, MD, PhD, Associate Scientist, Massachusetts Eye and Ear;, Associate Professor, Harvard Medical School

    Steven Grinspoon, MD, Chief, Metabolism Unit, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

    Alexandra-Chloé Villani, PhD, Investigator, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

  • 9:00 AM – 9:45 AM

    Therapeutic Psychedelics – Opportunities and Impact

    Moderators

    Maurizio Fava, MD

    Chair, Department of Psychiatry, Massachusetts General Hospital;

    Slater Family Professor of Psychiatry, Harvard Medical School

    Jason Gerberry

    Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

    Kerry Ressler, MD, PhD

    Chief Scientific Officer, McLean Hospital;

    Professor of Psychiatry, Harvard Medical School

    Panelists

    Cristina Cusin, MD

    Director, MGH Ketamine Clinic and Psychiatrist, Depression Clinical and Research Program, Massachusetts General Hospital;

    Associate Professor in Psychiatry, Harvard Medical School

    Daniel Karlin, MD

    Chief Medical Officer, MindMed

    John Krystal, MD

    Chair, Department of Psychiatry, Yale School of Medicine

    Jennifer Warner-Schmidt, PhD

    Vice President, Scientific Affairs, Transcend Therapeutics

  • 9:00 AM – 9:45 AM

    Innovations Advancing Community Health Equity

    Moderators

    Allen Lutz

    Health Care Services Analyst, BofA Global Research

    Elsie Taveras, MD

    Chief Community Health & Health Equity Officer, Mass General Brigham;

    Conrad Taff Endowed Chair and Professor of Pediatrics, Harvard Medical School

    Panelists

    Rebecca Mishuris, MD

    Chief Medical Information Officer, Mass General Brigham;

    Member of the Faculty, Harvard Medical School

    Claire-Cecile Pierre, MD

    Vice President, Community Health Programs, Mass General Brigham;

    Instructor in Medicine, Harvard Medical School

    Jorge Rodriguez, MD

    Clinician-investigator, Brigham and Women’s Hospital;

    Assistant Professor, Harvard Medical School

    Prabhjot Singh, MD, PhD

    Senior Advisor, Strategic Initiatives Peterson Health Technology Institute

  • 9:00 AM – 9:45 AM

    Earliest Detection

    Moderators

    James Brink, MD

    Enterprise Chief, Radiology, Mass General Brigham;

    Juan M. Taveras Professor of Radiology, Harvard Medical School

    David Louis, MD

    Enterprise Chief, Pathology, Mass General Brigham

    Benjamin Castleman Professor of Pathology, Harvard Medical School

    Jason Zemansky, PhD

    SMid-Cap Biotech Analyst, BofA Global Research

    Panelists

    Jasmeer Chhatwal, MD, PhD

    Associate Neurologist, Massachusetts General Hospital;

    Associate Professor of Neurology, Harvard Medical School

    Pradeep Natarajan, MD

    Director of Preventive Cardiology, Paul & Phyllis Fireman Endowed Chair in Vascular Medicine, Massachusetts General Hospital;

    Associate Professor of Medicine, Harvard Medical School

    Yakeel Quiroz, PhD

    Director, Familial Dementia Neuroimaging Lab and Director, Multicultural Alzheimer’s Prevention Program, Massachusetts General Hospital;

    Paul B. and Sandra M. Edgerley MGH Research Scholar;

    Associate Professor, Harvard Medical School

    Heidi Rehm, PhD

    Chief Genomics Officer, Massachusetts General Hospital;

    Professor of Pathology, Harvard Medical School

  • 9:00 AM – 9:45 AM

    Women’s Health Technology Revolution

    Moderators

    Tazeen Ahmad

    SMid-Cap Biotech Analyst, BofA Global Research

    Hadine Joffe, MD

    Executive Director of the Connors Center for Women’s Health and Gender Biology;

    Interim Chair, Department of Psychiatry, Brigham and Women’s Hospital;

    Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health, Harvard Medical School

    Panelists

    Keith Isaacson, MD

    Director of Minimally Invasive Gynecologic Surgery and Infertility, Newton Wellesley Hospital;

    Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

    Nawal Nour, MD

    Chair, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital;

    Associate Professor, Kate Macy Ladd Professorship, Harvard Medical School

    Kaveeta Vasisht, MD, PharmD

    Associate Commissioner, Women’s Health, U.S. Food and Drug Administration

    Alice Zheng, MD

    Principal, RH Capital

9:50 AM – 10:15 AM

Picasso Ballroom

Fireside

Fireside Chat

Moderator

David Brown, MD, President, Academic Medical Centers, Mass General Brigham; Mass General Trustees Professor of Emergency Medicine, Harvard Medical School

  • Hoe do you balance Private medicine with Public not for profit HealthCare
  • Healthcare delivery system can achieve that much in Human health
  • Resources for Equity: housing and services: Capacity and COst
  • Evolution of care close to home catalyst of the Pandemic – How government think about the right patient for the right care level
  • MGB 40-60 In-patients at Home – Largest Program in the State  – product needs to scale across all population though some do not have food security at home

Panelist

Kate Walsh, Secretary of Health and Human Services, State of Massachusetts

  • Stuart Bankrupcy – pstioents and providers involvement – structure challenges
  • Race and ethnicity – disparities, access and equity
  • Identify the challenge for Race and ethnicity
  • Focus to identify resources
  • Medicare & Medicaid – Human needs equity involve housing, food and home care – Public and Private sector cooperation
  • Pay for Performance
  • MA vs NYC – resources for welcoming new populations to the State of MA
  • Help finding Housing vs Shelter people
  • MA is the only State in the Union that is a Shelter State
  • People in our COuntry LEGALLY are in and out of shelters, new arrivals of skilled labor – temporary assistance to get jobs that we can’t find people to fill: CNA as example
  • MA has a community of shelters and medical center in the communities
  • Services for people that are at risk due to past life in home countries
  • Support for kids that do not speak English
  • Care and location: Keep care at home or SNF at home or in the community
  • Low income person at Home Hospital vs at MGB ?
  • Autist kids becoming Adult – how to care for ?

 

10:15 AM – 10:40 AM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Teresa Gomez-Isla, MD, PhD, MGH, Neurology, Memory division

  • Altzheimer’s biomarkers
  • Clinical trials lessons on drug benefits

Panelist

David Hyman, MD, Chief Medical Officer, Eli Lilly and Company

  • Cardio-metabolic – medicines redefining disease by medicines benefit to patients
  • Investment in manufacturing medicines for Obesity, demand continue to expand
  • Oral small molecule and scaling focus on Sleep apnea, half of the population have metabolic disease and heart failure
  • Extension Program with sustained weigh loss in pre-diabetes progressing into maintained weigh loss
  • Invest in R&D in the cardio-metabolic
  • Listed to community feedback on experience how the drugs in AD affected patients in the Community – learning about challenges in delivery innovation in AD – irreversible neurodegenerative diseases – prevent not to loose the patients entirely – brain function
  • Targeted therapies, genetic therapies
  • Past life Oncologist – delivered innovations into Cancer patients – genetic medicines
  • AD medicines are not accessible even to people of means, Drug delivery using PET spinal injections
  • Ten years horizons at Eli Lilly is common
  • Obligation to provide scientific evidence from clinical trials
  • Inventory of patients qualification to participate in Clinical trials
  • Oncology: Interactions in biologics, cell therapies, conjucate compounds
  • Renewal of Targeting antigens
  • In Oncology: Proportions of patients get long term disease control by molecules developed in Academic Centers.
  • Eli Lilly acquired a BioPharma with manufacturing capabilities
  • Innovations are core vs discount cash-flow, strategy is to look at the science due to capacity to develop innovations

10:40 AM – 11:20 AM

Picasso Ballroom

Disruptors

The Disruptors: Metabolic Power…Need It…Want it

Moderator

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Caroline Apovian, MD, MGH, HMS

  • Last ten years, from metabolic lessons of Bariatric patients
  • Treat obesity before surgery
  • product composition
  • multidisciplinary approach to obesity needs to be like in Oncology – multiple dsciplines
  • Bariatric and weigh regain like stent stenosis after surgery
  • Obesity dysfunction inflammation Gut-Brain transfer of hormones from the gut do not reach the brain to carb hunger socieaty is not signaled in the Brain and eating continued to mitigate hunger
  • Insurance must cover
  • Obesity Medicine – training 25 new practitioners to treat Obesity – Standards of Care, life style change
  • Primary care providers do not have resources to treat Life style component of
  • To reduce mortality by 20% by Bariatric surgery – No reduce of mortality by stenting – THAT I DISAGREE with

 

Panelists

David Hyman, MD, Chief Medical Officer, Eli Lilly and Company

  • non-peptide agonist, bariatric level for obesity
  • peptide injecting device
  • hormones and peptids activan inhibitor
  • hundred of million of people – scaling up
  • Adolescence with obesity will develop CVD, NASH
  • Epidemic of obesity the medicines are combating the epidemic
  • Vials, differential pricing, orals vs injectables
  • Productivity of work force, coverage by employers health insurance vs Government to handle coverage
  • 10 additional drug

Xiayang Qiu, PhD, CEO, Regor Therapeutics

  • six years ago, great opportunity peptide and biologics for lifetime disease of obesity
  • cardiovascular favorably = affected by reduction in weigh
  • Medicines that works start early at age 35

Harith Rajagopalan, MD, PhD, CEO & Co-Founder, Fractyl Health

  • Diet & Life Style
  • Eli Lilly and Novo Nordik – have great drugs
  • Patients stop using them before they see the benefit
  • durable long term of mentainance long-tern to stay on the drug
  • Past life coronary cardiologist: PCI vs surgery choice of care angioplasty vs open heart surgery
  • Bariatric surgery vs great medicines
  • may be angioplasty for Bariatric patients
  • Obesity is different than CVD
  • BC-BS coverage of obesity drugs because weight is gained back vs Statins – continual use control cholestrol
  • maintenance drugs in the field of Obesity are needed
  • cost of drugs will come down
  • more evidence on obesity drugs will affect Formulary

 

11:20 AM – 12:00 PM

Picasso Ballroom

The Innovation Gap: The Broader Impact of Metabolic Drugs on Related Diseases

Moderator

Jason Zemansky, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Patrick Ellinor, MD, PhD, MGH, HMS

Panelists

Craig Basson, MD, PhD, Chief Medical Officer, Bitterroot Bio

  • 17,000 patients obese no DM
  • prior CVD followed 3 yrs of treatment 6% mortality during the Trial
  • Death from CVD endpoint
  • weight at joining the trial, loss during the trial, benefir from the drug’
  • improve CVD not weigh loss
  • mechanism of Inflammation – drug, reduced atherosclerosis and reduced plaque and cytokins and inflammation improve CVD status
  • combination of life style and drugs GI axis systemic
  • cardiac artery disease: cholesterol, inhibit inflammatory signals plaque build on top of itself – approaches to remove debris macrophages in the plaque for artherosclerosis mechanism as CVD risk

Joshua Cohen, Co-CEO, Amylyx Pharmaceuticals

  • Bariatric surgery lower obesity
  • genetics, eating habits,
  • GLP-1 agonist developed

Punit Dhillon, CEO, Skye Bioscience

  • Phase II study combination therapy CVD and Obesity
  • optimize body composition – more productive on the body periphery
  • subtypes metabolic gains
  • Pharmacotherapy for obesity: mechanisms complementary life style change is a must have for long-term benefits
  • weight loss as a start before obesity treatment
  • co-morbidities of obesity

Justin Klee, Co-CEO, Amylyx Pharmaceuticals

  • Parkinson’s CNS peripheral Brain access therapies
  • revolution in metabolic disease treatment options, more studies for pathways to target the right patients for the right treatment
  • GLP-1 is energy regulator, Hypoglycemia is very dangerous

Rohan Palekar, CEO, 89bio

  • applications to obesity – data support
  • bariatric surgery intervention is not enough, NASH will not be impacted only by the surgery
  • NASH is a disease taking 25 years to develop
  • risk of fibrosis to set in Cirrhosis which is not curable

 

Concurrent Events

  • 12:15 PM – 1:00 PM

    ARPA-H: Opening New Frontiers in Health Innovations

    Panel of 5

    Glioblastoma Treatment Reinvented

    Moderators

    E. Antonio Chiocca, MD, PhD

    Chair, Department of Neurosurgery, Brigham and Women’s Hospital;

    Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School

    Charlie Yang, PhD

    Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

    Panelists

    Natalie Artzi, PhD

    Associate Professor of Medicine, Brigham and Women’s Hospital & Harvard Medical School

    Bryan Choi, MD, PhD

    Associate Director, Center for Brain Tumor Immunology and Immunotherapy, Massachusetts General Hospital;

    Assistant Professor of Neurosurgery, Harvard Medical School

    Alexandra Golby, MD

    Neurosurgeon;

    Director of Image-guided Neurosurgery, Brigham and Women’s Hospital;

    Professor of Neurosurgery, Professor of Radiology, Harvard Medical School

  • 12:15 PM – 1:00 PM

    Healthcare Corporate Venture

    Moderator

    Roger Kitterman

    Senior Vice President, Ventures and Business Development & Licensing, Mass General Brigham

    Managing Partner, Mass General Brigham Ventures

    Panelists

    Rahul Ballal, PhD

    CEO, Mediar Therapeutics

    Tim Luker, PhD

    VP, Ventures & West Coast Head, Eli Lilly

    James Mawson

    CEO, Global Corporate Venturing

  • 12:15 PM – 1:00 PM

    Inflammation Pathways

    Moderators

    Tazeen Ahmad

    SMid-Cap Biotech Analyst, BofA Global Research

    Katherine Liao, MD

    Associate Physician, Department of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital;

    Associate Professor of Medicine and Biomedical Informatics, Harvard Medical School

    Panelists

    Jessica Allegretti, MD

    Director, Crohn’s and Colitis Center, Brigham and Women’s Hospital;

    Associate Professor of Medicine, Harvard Medical School

    Andrew Luster, MD, PhD

    Chief, Division of Rheumatology, Allergy and Immunology;

    Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital;

    Persis, Cyrus and Marlow B. Harrison Professor of Medicine, Harvard Medical School

    Thorsten Mempel, MD, PhD

    Associate Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital;

    Professor of Medicine, Harvard Medical School

  • 12:15 PM – 1:00 PM

    Hospital at Home

    Moderators

    Joanna Gajuk

    Health Care Facilities and Managed Care Analyst, BofA Global Research

    Heather O’Sullivan, MS, RN, AGNP

    President, Mass General Brigham Healthcare at Home

    Panelists

    O’Neil Britton, MD

    Chief Integration Officer & Executive Vice President, Mass General Brigham

    Jatin Dave, MD

    Chief Medical Officer, MassHealth;

    Director of Clinical Affairs, UMass Chan Medical School

    Chemu Lang’at

    Chief Operating Officer, Best Buy Health

1:05 PM – 1:45 PM

Picasso Ballroom

Pioneering Digital Transformation

Moderator

Liz Kwo, MD, Chief Commercial Officer, Everly Health

  • Infrastructure
  • AI used for

Panelists

Anna Åsberg, Vice President, AstraZeneca Pharmaceuticals

  • Massive data bases organize
  •  AI to augment intelligence inside the data

Tyler Bryson, Corporate Vice President, US Health & Public Sector Industries, Microsoft Corporation

  • Do we have platforms to serve new problem
  • Regulatory changes require visiting use cases
  • Pharma has the research data, providers have EMR – Microsoft builds new models using that data
  • Tumor imaging data was processed and new pattern recognition done on data of these tumors. New patterns are now a subject for research, just identified inside the data
  • Trust in Healthcare
  • NYC and Microsoft developed a System for small businesses to access city resources
  • Works with Academic institutions: Programs at Harvard and Princeton to train students by Microsoft employees on MIcrosoft AI technologies that as they graduate there will be trained new AI-trained employees
  • collaborations

Aditya Bhasin, BofA

  • AI in Banking: Bias, security
  • AI virtual system analytics to provide insight for scaling

Jane Moran, MGH

  • Network, Data structure needs updates
  • technology to help clinicians
  • care team to work with Generative AI to assist in e-mail reading and problem solving
  • Healthcare equity – avoid Bias
  • AI is not an answer to every problem
  • innovate at scale: using Epic and Microsoft
  • Clinical data structure for LLM, AI to renovate administrative processes inside MGH
  • Data structure for transperancy
  • Digital Rounds like Medical ROunds audit problems
  • equity in data

1:45 PM – 2:25 PM

Picasso Ballroom

Capital Formation: Putting Money to Work – State of Affairs in Capital Markets

Moderators

John Bishai, PhD, BofA

  • valuations went down

Brendan Singleton, Healthcare Equity Capital Markets, BofA Securities

  • what impact Capital flow

Emma Somers-Roy, Chief Investment Officer, Mass General Brigham

Panelists

Chris Garabedian, Chairman & CEO, Xontogeny; Venture Portfolio Manager, Perceptive Advisors

  • Valuations done with comparables for IPO
  • Not quick to invest in companies, responsible behavior
  • Private rounds, Biotech and Pharma strategic partners
  • M&A stable requires are exciting valuation
  • foundations, institutional investors – level of interest is related to valuations number of years to exit
  • Peak sale, Public markets different than Private markets
  • Obesity is a crowd space, diferentiation is important
  • Exit tow ways: year for IPO natural acquirer – Who is he??
  • Cancer was a dominant now CNS, Cardio-metabolic, ophthalmology
  • size of market – Cancer was attractive, less in 2024
  • Early venture investor: 50-100MM valuation to 2Bil
  • CMS has discounting since profits are been realize at present time
  • Patents`
  • Presidential election
  • investors scarce pushed fewer mega rounds 100MM financing requires early clinical data
  • Hedge fund very conservative with valuations
  • Downsize in Biotech is over

Arjun Goyal, MD, Vida Ventures

  • Investment in private markets
  • 2019-2021 – IPOs on narratives and proof of concept, only only, no financials
  • M&A or Partnering – financial risk clinical data point
  • validation of team success
  • size of market is very important
  • Innovation matters always in Pharma, prospects for Biotech very bright
  • what is HOT in a moment
  • combination therapies
  • Life cycle: compound right gene, financing history, fundamentals
  • calibration of market valuations

 

2:25 PM – 2:50 PM

Picasso Ballroom

Fireside

Lessons Learned Shaping New Horizons: Visionary Change Agent Perspectives

Moderator

Yvonne Hao, Secretary of Economic Development, Commonwealth of Massachusetts

  • accelerate AI adoption by nurses, How do you do that??
  • Public private partnerships
  • If you have a blank slate – do it differently

Great impact of Cleveland Clinic

Panelists

Delos “Toby” Cosgrove, MD, Executive Advisor; former CEO & President, Cleveland Clinic

  • Housing, education, research beyond healthcare
  • Reduce cost in healthcare, call centers by AI: equipment to measure BP every 4 hours
  • Technology is approved 13 years to become standard of care
  • COST in healthcare requires SALVATION
  • mistakes by leadership
  • Regulators have their share in current situation of Healthcare
  •  Leadership in Health care must change

Marc Harrison, MD, Co-founder & CEO, Health Assurance Transformation Corp. (HATCo)

  • collaborate with competitors
  • AI is a tool not a solution
  • Streamline processes to reduce costs
  • Government should not solve the Healthcare problem
  • Residents are victims of leaders mistakes
  • Only healthcare industry sees the medical records of all the population
  • gene therapy, innovations to change healthcare and get financial solvency

2:50 PM – 3:15 PM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

Andrew Bressler, Washington Healthcare Policy Analyst, BofA Global Research

  • What is coming up in the next two years
  • Are you growing and Hiring?

Yvonne Hao, Secretary of Economic Development, Commonwealth of Massachusetts

  • AI – what is the potential for Healthcare
  • MA to work with ARPA-H

Panelist

Renee Wegrzyn, PhD, Director, Advanced Research Projects Agency for Health – A Federal Governmental Agency

  • ARPA-H Model was introduce under the Advanced Research Projects Agency for Health
  • Hired 21 Program Managers to manage Health initiatives in research
  • Health is not a partizan affair
  • Bring young innovators, mantored by experiences healthcare professionals
  • cellular therapeutics is an example selected to advanced the field
  • Data driven – looking at +100 project approved by government agency
  • Governtment, Academia, Private sector – SOLICITATIONS for solving a research problem
  • Technical merit in judging applications
  • Value-baced pricing – data to influence policy FDA, NIH collaboration
  • FDA to finance projects spending
  • Pediatrics
  • President announced a program for ARPA-H to work on
  • Investors are welcome to review proof of concepts of ARPA-H
  • Return on Investment for all Americans’ Tax payers money
  • Yes, growing and hiring. $1.5 milion budget

 

 

3:15 PM – 3:20 PM

First Look

3:20 PM – 3:35 PM

Selector of Winner: Doug Marshall & Paul Anderson, MD, PhD

 

3:35 PM – 4:15 PM

Picasso Ballroom

Disruptors

The Disruptors: The Biologic Revolution in Radiotherapies

Moderator

John Bishai, PhD, Global Healthcare Investment Banking, BofA Securities

Umar Mahmood, MD, PhD, MGH, HMS

Panelists

Amos Hedt, Chief Business Strategy Officer, Perspective Therapeutics

  • imaging used to deliver the therapeutics before the drug touch the patient to calculate toxicity
  • PL-1 combined with radiotherapy synergistics results
  • immunogenic combination therapy, in presence of these agents, immune response reaction in the immune cells

Matthew Roden, PhD, President & CEO, Aktis Oncology

  • Conjugates – delivery direct to tumors
  • Opportunity two targets: (1) SSTA2 marker (2) xx
  • WHen agent inside the tumor, shrinkage and no emergence of cell nascent 
  •  optimization design
  • Treatment break for patients and families

Philip Kantoff, MD, Co-Founder & CEO, Convergent Therapeutics

  • Radio-pharmeceutics : 10 days half-life carrier not a target for small molecules Data on 120 patient, namo robust response synergy of antibody and molecule
  • image alphas
  • durable responses

Matt Vincent, PhD, AdvanCell Isotopes

  • ROS species generated in the tumor
  • peptides, protein binders
  • paradigm shift in delivery of oncology therapeutics directly to tumors

Lena Janes, PhD, Abdera Therapeutics

  • isotope will deliver the payload without damaging the DNA and healthy tissue
  • target different types of tumors, different half-life
  • Radiation therapy using isotopes id one of two modalities: tumor in and tumor out approach
  • screen for patient for the translational therapy
  • Next generation of products will come, now it is the beginning of these agents

4:20 PM – 4:45 PM

Picasso Ballroom

Fireside

Fireside Chat

Moderator

Michael Ryskin, Life Science Tools & Diagnostics Analyst, BofA Global Research

  • Precision Medicine was it a paradigm shift??
  • Acquisition of manufacturing capabilities
  • research, manufacturinf line blurred
  • WHat excites you the most

Panelist

Marc Casper, Chairman, President & CEO, Thermo Fisher Scientific

  • Enabling Life sceinces, Pharmaceutical industries $1.5Billion internal investment annually
  • AI increasing knowledge
  • How is Precision Medicine applied? Sequencing in Cancer accelerated the Genomics information in use for 24 hours response of the sequence – adopted around the World.
  • at MGH lung cancers are treated with genomic sequencing
  • identification of the patients suitability for a targeted treatment
  • treatment during pregnacy at home vs hospitalization
  • History of company: Tools first: Mass spectrometry, one year for one sequence, protein identification and carrying to Mass spectrometry
  • Interactions need understanding acquiring electro spectrometry allowing analytical chemistry on proteins
  • Broad range of products: Clinical research to meet regulatory requirements entry into Reagents products.
  • Clinical Trials made effective by Thermo Scientific Products
  • Capabilities in registries, patient safety in psoriasis
  • Large role in experimental medicine drives efficiency in LABS
  • SIze of customers: small Biotech and large Pharma
  • Manufacture medicines: work with partnersbuilt by acquisitions small molecules,
  • 100 engagements research, supply chain making medicines available at sites
  • Role for AI at Thermo Scientific:
  1. Productivity – Cost effective for processes in use by 120,000 employees
  2. Super customer interaction perfected by interogations with internal manuals to provide answers quickly
  3. Improvement of products
  • Excitement Points: Responsiveness to COVID pandemic
  • New medicine development

4:50 PM – 5:30 PM

Picasso Ballroom

The Reemergence of ADCs, Precision Medicine, T-cell engagers, and Bispecifics: Oncology at Its Finest

 

Moderators

John Bishai, PhD, BofA

  • Approach to AI
  • Strategy regarding clinical trial design, vs molecule design

Justin Gainor, MD, MGH, HMS

  • How strategies are developed and then modified?
  • immune therapies work better open new paradeigm

Panelists

Moitreyee Chatterjee-Kishore, PhD, Head of Development, Immuno-Oncology and Cancer Cell Therapy, Astellas Pharma Inc.

  • cancer – first line of treatment vs 2nd and 3rd
  • Precision medicine more precise
  • mix and match immunotherapy and other modalities
  • small molecule early on
  • molecule formulation is science and art
  • Stratify the patient population early on
  • Help needed to design better trials
  • Research is key for molecule design

Niall Martin, PhD, CEO, Artios Pharma

  • peptide chemistry
  • molecule design had options several are applied
  • biomarker driven event in development cycle
  • strategy of biomarkers – lack structure
  • effect of combination therapy on survival?

Chris Varma, PhD, Co-founder, Chairman & CEO, Frontier Medicines

 

5:30 PM – 8:30 PM

South Lawn Tent

Attendee Reception and Dinner

Moderator

Anne Oxrider

Senior Vice President, Benefits Executive, Bank of America

Panelist

Deepak Chopra, MD

Founder, The Chopra Foundation

Wednesday, September 25, 2024

8:30 AM – 8:55 AM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

David Ting, MD, Associate Clinical Director for Innovation, Mass General Cancer Center; Associate Professor of Medicine, Harvard Medical School

  • Innovation is the foundation of the future
  • Creative thinking vs one agent and one target
  • Openness is much appreciated

Jason Zemansky, PhD, SMid-Cap Biotech Analyst, BofA Global Research

  • On WSJ article on M&A in Biotech attributing decline in M&A of Biotech companies due to LACK of Innovations
  • Q from audience: organizational structure and innovation
  • Vision on leveraging Partnerships

Panelist

Tadaaki Taniguchi, MD, PhD, Chief Medical Officer, Astellas Pharma

  • Pharma and Biotech heavy betting on new medicines in Oncology
  • Astellas Pharma is different than other Pharma companies
  • We focus on Oncology and in combination therapies as a priority
  • Investment pay attention to Leadership priorities
  • One product vs BEST combination therapy for best treatment and outcomes
  • Innovations come from anywhere
  • ADCs: Target, payload emerged recently by a partnership
  • Collaborations: several pathways, several modalities, several combinations therapies
  • Partnership requires greater flexibility
  • Created Small flexible Labs to enable to innovate with Partners, “we can’t innovate alone”

9:00 AM – 9:40 AM

Picasso Ballroom

Disruptors

The Disruptors: The Role of Pathway Inhibition in Inflammation and Inflammatory Diseases

Moderators

Tazeen Ahmad, SMid-Cap Biotech Analyst, BofA Global Research

  • Are you using AI
  • Neuroinflammation

Cynthia Lemere, PhD, BWH, HMS

  • What systems are primarily impacted by the Immunes system
  • Drug delivery for inflammation huge area
  • Getting antibodies to the Brain
  • Precision medicine, genetics,specific person with specific immune disease

Panelists

Jo Viney, PhD, Cofounder, President & CEO, Seismic Therapeutic

  • Pandemics highlighted the impact of the immune system
  • Targeting cytokines in specific locations – hew approach
  • Modalities on hand: protein degradation mediation by bringing two cells together
  • AI is used for Patient stratification
  • AI to be used in Pathways involved in disease process to identify Biologics, PROTAC,
  • AI and ML for training models from interaction between proteins
  • ChatGPT to predict interactions among proteins
  • Immune disease and remission bust the immune system to improve quality of life of patient undergoing interventions
  • T-cell engaggers – in cases of refractory – great approach for boosting the immune system: removal of antibidies, recycling antibodies,
  • Two ends: Cell depletion vs Early detection
  • Therapy is every 6 months, cell depletion takes 3 months to come back.
  • Target immune system in the periphery,
  • Immune system in neurodegenerative diseases: Parkinson’s local modulation to penetrate neurological system
  • Markers to cross the BBB or not cross in neurological diseases
  • Immune disease is POLYGENIC multiple o=etiologies, mutation, genetics, which cell and which pathway to target a therapeutics: Biologics
  • Patient stratification is key for Precision Medicine at the cell level
  • T-cell, B-cell, Cytokines and antibodies mediated disease
  • ADGs degradation

9:45 AM – 10:10 AM

Picasso Ballroom

H. Jeffrey Wilkins, MD, Abcuro
  • Inflammation play a role in activating the immune system
  • zin the days of Medical School: inhibition of cytokines
  • Today: specificity to target cells for depletion
  • Specific biomarkers for response to therapies
  • cell types by mutations and physiology and causality in the inflammation area: we know why they have inflammation we need to learn interventions for inflammation
  • Asthma in the 40s as an inflammatory disease
  • assess treatment of inflammation
  • Neuro-inflammation – not well understood
  • What is the cause that drive the disease: understanding encephalitis?
NiranJana Nagarajan, PhD, MGB Ventures
  • Biology is the driver not AI
  • depletion of cells in a certain stage
  • Translation from disease to other diseases in the case of cell therapy potential – active area companies are trying solutions
  • Inflammation is a huge challenge to treat

 

Fireside

Fireside Chat

Moderators

Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, Brigham and Women’s Hospital; Harriet Ryan Albee Professor of Medicine, Harvard Medical School

  • Pathways in vaccine design
  • How to educate population on Vaccines
  • other approaches than vaccines

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

  • Vaccine approval
  • Next generation vaccines

Panelist

Stéphane Bancel, CEO, Moderna

  • Vaccine design: long term vaccines weakens in aged population
  • data on role of AVV in Multiple Sclerosis
  • working on in the US vs France, Netherland in Europe different approaches
  • Vaccine for HIV
  • Vaccine was approved last year for children, pharmacies shortage
  • Season of FLu three times more vaccines in use
  • Employees run vaccine clinics on site
  • Vaccines not related to COVID
  • Misinformation from COVID vaccine
  • 5% of COVID hospitalized were on the booster
  • Combination vaccines for high risk populations
  • Healthcare providers need to be involved in Education, many do not have an interest in the education on vaccines
  • Local stories from Vaccine manufectures and developer to be used in education in the communities
  • Individual DNA cancer celll signature of the cancer  – data over time for development of vaccine to cancer many more tumor types are needed
  • Checkpoints in early disease
  • biopsy are too expensive
  • Side effect studies going on
  • mono-therapy vs immunotherapy costs involved
  • Naive virus to get into the Liver two diseases – cassets for sose management
  • Recombinant antibodies technology from the 70s
  • PD-1
  • COVID – was nto in the plan for development – design in silicon in two weeks – no change after this design
  • 10:10 AM – 10:20 AM

10:20 AM – 11:00 AM

Picasso Ballroom

The Innovation Gap: Understanding the Role of Cell Therapies in Autoimmune Disease

Moderator

Charlie Yang, PhD

Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

  • TCM
  • CAR-T
  • advantages of each cell type

Angele Shen, MGB Innovations

  • CAR-T
  • What would be a quick breakthrough?

Panelists

Jeff Bluestone, PhD, CEO & President, Sonoma Biotherapeutics

  • Cell therapy for cell depletion elimination of B-cells like its role in Multiple Sclerosis
  • Working with regulatory T-cells
  • Population of cells to study: T-cells master regulator in multiple ways – produce metabolic factors, infection tone in activation of other cells
  • Biology of cell: RNA, DNA
  • TCR – target antigens in tissues they are in in immune suppression
  • FInding the right peptide bindes to a certain MAC
  • CAR-T – recornize the cells in the local milieu like in patients with RA as an autoimmune disease
  • Clinical models ascertain cell types involvement leading to clinical trial insights then to therapies on a decision tree
  • recent data on CAR-T immune response in allogeneic for potential use in neurodegenerative diseases
  • patients and companies over react on immune therapy: Patients and Science vs hype
  • next generation: POC,
  • Gene therapy specificities vs Cell therapies – each approach will develop a different drug
  • FDA and NIH has in 11/2023 a meeting on Regulation of Cell therapy on stability and their approach to immune disease where there are already several drugs
  • approvals challenges companies
  • Price, too expensive a treatment is cell therapy

Chad Cowan, PhD, Executive Advisor, Century Therapeutics

  • use Natural Killer cells to elicit long-term immune response, T-cells,
  • active Beta cells]Regulatory monitoring use
  • DM – regulatory cells made from Stem cells
  • mission durable response
  • Clinical issues – not easy way for treatment wiht a cell line and bioreactors and modalities less similar to autologoous celles
  • CAR-T in oncology lessons now are transferred to Immune disease
  • Cell therapy requires technologies to mature multiple modalities and multiple drugs not one cell therapy for all immune diseases
  • Stability of the therapy vs rejection by immune system
  • FDA making cells is not as making drugs – higher level of scrutiny for cell therapy
  • SYNTHETIC BIOLOGY on B-cells for future breakthrough

Samantha Singer, President & CEO, Abata Therapeutics

  • Immune response involve many cell types in many diseases
  • Oncology the use of T-cells as tissue residents staying in tissue long time
  • Specific biology of the disease and regulatory cells receptors optimizing TCR presentation in pathology of tissue residents phyno types
  • activate in nervous system or in pancreas – intersection of cell biology with disease biology
  • Market feasibility – scaling, biology, pathology for reimbursement
  • antibody therapy may be appropriate than cell therapy is only a novel option
  • Cell manufacturing requires optimization of process, companies commercializing across all cell types
  • comprehensive approach for systemic immune suppression
  • : healthy tissue vs diseased tissue with cell theray implanted cells as residents in tissue
  • clinical data on product performance and on the biology reactions

11:00 AM – 11:40 AM

Picasso Ballroom

Unmet Clinical Needs: 100 Harvard KOLs Weigh In

Moderators

Jose Florez, MD, PhD, Physician-in-Chief and Chair, Department of Medicine, Massachusetts General Hospital; Professor, Harvard Medical School

  • 40 minutes to deal with big needs collected from 100 faculties at Harvard Medical School
  • The ten issues on one slide
  • How could we use compute to distill data

Bruce Levy, MD, Physician-In-Chief and Co-Chair, Department of Medicine, Brigham and Women’s Hospital; Parker B. Francis Professor of Medicine, Harvard Medical School

  • Transformation from the Present to the Future
  • identifying the needs
  • Infectious diseases: Rapid diagnostics need
  • resistance to antibiotics and metabolic reactions endogenous
  • Pandemics globally of diseases erradicated in the past: Pox, polio
  • Improving health in Geriatrics, not population growing but geriatric population growing. Beyong age 60 a citizen will use 1 or 2 physicians each
  • 7,000 diseases, Genetic diseases requires integration and innovations in therapy
  • Innovations in Home devices

Panelists

Rox Anderson, MD, Lancer Endowed Chair of Dermatology;, Director, Wellman Center for Photomedicine, MGH; Professor of Dermatology, HMS

  • Access to data across institutions

Nicole Davis, PhD, Biomedical Communications

  • We asked 104 expert practitioners, content collected was analyzed
  1. detection early
  2. keeping the Human brain healthy
  3. geriatrics Medicine, aging and compound effects on health system with aging and Health equity
  • Bias in Data

Jean-François Formela, MD, Partner, Atlas Venture

  • genetic information used in therapeutics design

Steven Greenberg, MD, Neurologist, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School

  • Human genome completed in 1999, human genetic diseases were discovered learn about the disease at the tissue level with genomics and a system approach
  • Pathogenic drivers, systme integration by therapeutics approaches to pathways multiple cytokines in allergic reactions Pfizer had two biomarkers and therapies for systemic biology of disease
  • Pediatrics has its own challenges
  • Imaging medicine
  • Living longer at a lower cost  – HOW TO ACHIEVE THAT?
  • growth abnormality in children: Body growth and Skull shrink

John Lepore, MD, CEO, ProFound Therapeutics;, CEO-Partner, Flagship Pioneering

  • Pathway, targeting therapy to patients in a System biological approach
  • Database of systme biology has missing components not included in the Human genome project – completion of the Data
  • Definition of End points needs revisiting
  • Identifying specific populations vs getting quickly to market
  • Diseases of aging: Muscles diseases – how to promote improvement in muscle mass

CONCLUSIONS

  1. Gray Tsunami
  2. Brain health
  3. Cancer treatment paradigm shift
  4. Fibrosis in many diseases
  5. infectious disease in changing World
  6. Equity in HC
  7. Clinical Data is VAST
  8. Systemic view of Human disease
  9. New approaches to Psychaitry
  10. Rare disease treatment needs a charter

In addition,

  • new generation of pain treatment
  • skin treatment new drugs
  • Chronic disease: improve treatment and prevention.
  • Obesity medicine – new discipline in a new Era

11:45 AM – 12:30 PM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

Tazeen Ahmad, SMid-Cap Biotech Analyst, BofA Global Research

  • FDA sets criteria  – How is that done?
  • Autoimmune disease therapies – What is in the horizon?

 

Paul Anderson, MD, PhD, Chief Academic Officer, Mass General Brigham;

  • drug development
  • drug pricing in Europe
  • New book
  • RA needs more medicines

UNCONTROLLED SPREAD

In Uncontrolled Spread, a New York Times Best Seller, Dr. Scott Gottlieb identifies the reasons why the US was caught unprepared for the pandemic and how the country can improve its strategic planning to prepare for future viral threats.

Panelist

Scott Gottlieb, MD, Physician; Former Commissioner, Food and Drug Administration (2017-2019)

  • FDA approval 1st gene therapy in his tenure
  • Price of drugs: efficatious vs time to deveop
  • competitors in the marketplace are there for market share
  • New Book: Episodes in the FDA, appproval process at FDA, Gene therapy 1st in class approved – a special moment. Back in 1980s era translated to antibodies, to T-cell pioneering work.
  • Publisher worried it will not sell very well
  • FDA had concerns about manufacturing aspects
  • In 2024 we understand Biologics on novel platforms
  • Worries that Medicare will not reimbursement  and cover the new therapies: Cell therapy
  • Statins approval had a known very large market vs Cell therapy not known which Cancer patients will benefit???
  • Black box involved in Autoimmune, studies bring exciting results
  • In 2018 – needs arise for early approved of drugs in AD, amyloid plaque – change in thinking and is controversial
  • In early 2020, change in settings of clinical trials, placido no more the only way for Randomized trials
  • Approval for AD drug vs othe indication – the process is difference (DMD a case to think about)
  • AI & NLP: Train on data of 10,000 lesions
  • FDA choose not to regulate AI the physician is in the Middle
  • Who is wrong: CHatGPT or the clinician ?
  • Data set on gene may represents NEW biologies that Physicians had not seen before
  • Data validation on medical devices and their approval after regulating them
  • Diagnostics tests: Validation Panels are involved
  • Regulated on input data vs Output data and validate the input data
  • Platforms are needed for regulation of AI involvement in the drug discovery and the drug approval process
  • investment in this platforms will be done by Whom?? It will come
  • Framework for AI at FDA: Regulatory gray data for applications and standards for output – not a novel regulatory concept
  • If AI will be applied widely, I/O accuracy is a must have
  • may be achievable soon?
  • FDA is evolutionary organization in its decision process NOT a REVOLUTIONARY organization. Simulation work started in 2003, 40 people doing that then.
  • Recently, new team in Agency working of Safety with tools and technologies that are common in Science  – Approvals to drug labels and off labels that 20 years ago would not have happened
  • Tolerance for higher prices is to support Private sector that brings the innovating drugs to market

 

SPEAKERS

C-Suite Speakers

Faraz Ali

CEO, Tenaya Therapeutics

Peter Anastasiou

CEO, Capsida Biotherapeutics

Paul Anderson, MD, PhD

Chief Academic Officer, Mass General Brigham; K. Frank Austen Professor of Medicine, Harvard Medical School

Rahul Ballal, PhD

CEO, Mediar Therapeutics

Stéphane Bancel

CEO, Moderna

Craig Basson MD, PhD

Chief Medical Officer, Bitterroot Bio

Jeff Bluestone, PhD

CEO & President, Sonoma Biotherapeutics

Albert Bourla, PhD

Chairman & CEO, Pfizer

O’Neil Britton, MD

Chief Integration Officer & Executive Vice President, Mass General Brigham

Marc Casper

Chairman, President & CEO, Thermo Fisher Scientific

Joshua Cohen

Co-CEO, Amylyx Pharmaceuticals

Delos “Toby” Cosgrove, MD

Executive Advisor; former CEO & President, Cleveland Clinic

Jatin Dave, MD

Chief Medical Officer, MassHealth; Director of Clinical Affairs, UMass Chan Medical School

Punit Dhillon

CEO, Skye Bioscience

Steve Favaloro

Chairman & CEO, Genezen

John Fish

Chairman & CEO, Suffolk

Alexandria Forbes, PhD

CEO, MeiraGTx

Niyum Gandhi

CFO & Treasurer, Mass General Brigham

Chris Garabedian

Chairman & CEO, Xontogeny; Venture Portfolio Manager, Perceptive Advisors

Lucas Harrington, PhD

Co-Founder & CSO, Mammoth Biosciences

Marc Harrison, MD

Co-founder & CEO, Health Assurance Transformation Corp. (HATCo)

Amos Hedt

Chief Business Strategy Officer, Perspective Therapeutics

Rod Hochman, MD

President & CEO, Providence

David Hyman, MD

Chief Medical Officer, Eli Lilly and Company

Philip Kantoff, MD

Co-Founder & CEO, Convergent Therapeutics

Daniel Karlin, MD

Chief Medical Officer, MindMed

Reshma Kewalramani, MD

CEO & President, Vertex Pharmaceuticals

Justin Klee

Co-CEO, Amylyx Pharmaceuticals

Anne Klibanski, MD

President & CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Samarth Kulkarni, PhD

CEO, CRISPR Therapeutics

Liz Kwo, MD

Chief Commercial Officer, Everly Health

Adam Landman, MD

Chief Information Officer & SVP, Digital, Mass General Brigham; Associate Professor of Emergency Medicine, Harvard Medical School

Chemu Lang’at

Chief Operating Officer, Best Buy Health

Paul LaViolette

Managing Partner & COO, SV Health Investors

John Lepore, MD

CEO, ProFound Therapeutics; CEO-Partner, Flagship Pioneering

Christopher Longhurst, MD

Chief Medical & Digital Officer, UC San Diego Health

Kevin Mahoney

CEO, University of Pennsylvania Health System

Niall Martin, PhD

CEO, Artios Pharma

James Mawson

CEO, Global Corporate Venturing

Mark McKenna

Chairman & CEO, Mirador Therapeutics

Jane Moran

Chief Information and Digital Officer, Mass General Brigham

William Morris, MD

Chief Medical Information Officer, Google Cloud

Rohan Palekar

CEO, 89bio

Raju Prasad, PhD

Chief Financial Officer, CRISPR Therapeutics

Xiayang Qiu, PhD

CEO, Regor Therapeutics

Harith Rajagopalan MD, PhD

CEO & Co-Founder, Fractyl Health

Shiv Rao, MD

CEO & Founder, Abridge

Kerry Ressler, MD, PhD

Chief Scientific Officer, McLean Hospital; Professor of Psychiatry, Harvard Medical School

Matthew Roden, PhD

President & CEO, Aktis Oncology

Sandi See Tai, MD

Chief Development Officer, Lexeo Therapeutics

Samantha Singer

President & CEO, Abata Therapeutics

Joanne Smith-Farrell, PhD

CEO & Director, Be Biopharma

Emma Somers-Roy

Chief Investment Officer, Mass General Brigham

Adam Steensberg, MD

President & CEO, Zealand Pharma

Tadaaki Taniguchi, MD, PhD

Chief Medical Officer, Astellas Pharma

Elsie Taveras, MD

Chief Community Health & Health Equity Officer, Mass General Brigham; Conrad Taff Endowed Chair and Professor of Pediatrics, Harvard Medical School

Jo Viney, PhD

Cofounder, President & CEO, Seismic Therapeutic

Ron Walls, MD

Chief Operating Officer, Mass General Brigham; Neskey Family Professor of Emergency Medicine, Harvard Medical School

Christophe Weber

President & CEO, Takeda

Fraser Wright, PhD

Chief Gene Therapy Officer, Kriya Therapeutics

Speakers

Anna Åsberg

Vice President, AstraZeneca Pharmaceuticals

Tazeen Ahmad

SMid-Cap Biotech Analyst, BofA Global Research

Jessica Allegretti, MD

Director, Crohn’s and Colitis Center, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

Rox Anderson, MD

Lancer Endowed Chair of Dermatology; Director, Wellman Center for Photomedicine, MGH; Professor of Dermatology, HMS

Katherine Andriole, PhD

Director of Academic Research and Education, Mass General Brigham Data Science Office; Associate Professor, Harvard Medical School

Caroline Apovian, MD

Co-Director, Center for Weight Management and Wellness, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Vanita Aroda, MD

Director, Diabetes Clinical Research, Brigham and Women’s Hospital; Associate Professor, Harvard Medical School

Natalie Artzi, PhD

Associate Professor of Medicine, Brigham and Women’s Hospital & Harvard Medical School

John Bishai, PhD

Global Healthcare Investment Banking, BofA Securities

David Blumenthal, MD

Professor of Practice of Public Health and Health Policy, Harvard TH Chan School of Public Health; Research Fellow, Harvard Kennedy School of Government; Samuel O. Thier Professor of Medicine, Emeritus, Harvard Medical School

Giles Boland, MD

President, Brigham and Women’s Hospital and Brigham and Women’s Physicians Organization; Philip H. Cook Distinguished Professor of Radiology, Harvard Medical School

Andrew Bressler

Washington Healthcare Policy Analyst, BofA Global Research

James Brink, MD

Enterprise Chief, Radiology, Mass General Brigham; Juan M. Taveras Professor of Radiology, Harvard Medical School

David Brown, MD

President, Academic Medical Centers, Mass General Brigham; Mass General Trustees Professor of Emergency Medicine, Harvard Medical School

Tyler Bryson

Corporate Vice President, US Health & Public Sector Industries, Microsoft Corporation

Jonathan Carlson, MD, PhD

Director of Chemistry, Center for Systems Biology, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School

Miceal Chamberlain

President of Massachusetts, Bank of America

Moitreyee Chatterjee-Kishore, PhD

Head of Development, Immuno-Oncology and Cancer Cell Therapy, Astellas Pharma Inc.

Dong Feng Chen, MD, PhD

Associate Scientist, Massachusetts Eye and Ear; Associate Professor, Harvard Medical School

Jasmeer Chhatwal, MD, PhD

Associate Neurologist, Massachusetts General Hospital; Associate Professor of Neurology, Harvard Medical School

E. Antonio Chiocca, MD, PhD

Chair, Department of Neurosurgery, Brigham and Women’s Hospital; Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School

Bryan Choi, MD, PhD

Associate Director, Center for Brain Tumor Immunology and Immunotherapy, Massachusetts General Hospital; Assistant Professor of Neurosurgery, Harvard Medical School

Deepak Chopra, MD

Founder, The Chopra Foundation

Yolonda Colson, MD, PhD

Chief, Division of Thoracic Surgery, Massachusetts General Hospital; Hermes C. Grillo Professor of Surgery, Harvard Medical School

Chad Cowan, PhD

Executive Advisor, Century Therapeutics

Cristina Cusin, MD

Director, MGH Ketamine Clinic and Psychiatrist, Depression Clinical and Research Program, Massachusetts General Hospital; Associate Professor in Psychiatry, Harvard Medical School

Nicole Davis, PhD

Biomedical Communications

Marcela del Carmen, MD

President, Massachusetts General Hospital and Massachusetts General Physicians Organization (MGPO); Executive Vice President, Mass General Brigham; Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Gerard Doherty, MD

Surgeon-in-Chief, Mass General Brigham Cancer; Surgeon-in-Chief, Brigham and Women’s Hospital; Moseley Professor of Surgery, Harvard Medical School

Liz Everett Krisberg

Head of Bank of America Institute

Maurizio Fava, MD

Chair, Department of Psychiatry, Massachusetts General Hospital; Slater Family Professor of Psychiatry, Harvard Medical School

Keith Flaherty, MD

Director of Clinical Research, Mass General Cancer Center; Professor of Medicine, Harvard Medical School

Jose Florez, MD, PhD

Physician-in-Chief and Chair, Department of Medicine, Massachusetts General Hospital; Professor, Harvard Medical School

Jean-François Formela, MD

Partner, Atlas Venture

Fritz François, MD

Executive Vice President and Vice Dean, Chief of Hospital Operations, NYU Langone Health

Joanna Gajuk

Health Care Facilities and Managed Care Analyst, BofA Global Research

Jason Gerberry

Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

Gad Getz, PhD

Director of Bioinformatics, Krantz Center for Cancer Research and Department of Pathology; Paul C. Zamecnik Chair in Cancer Research, Mass General Cancer Center; Professor of Pathology, Harvard Medical School

Alexandra Golby, MD

Neurosurgeon; Director of Image-guided Neurosurgery, Brigham and Women’s Hospital; Professor of Neurosurgery, Professor of Radiology, Harvard Medical School

Allan Goldstein, MD

Chief of Pediatric Surgery, Massachusetts General Hospital; Surgeon-in-Chief, Mass General for Children; Marshall K. Bartlett Professor of Surgery, Harvard Medical School

Scott Gottlieb, MD

Physician; Former Commissioner, Food and Drug Administration (2017-2019)

David Grayzel, MD

Partner, Atlas Venture

Steven Greenberg, MD

Neurologist, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School

Steven Grinspoon, MD

Chief, Metabolism Unit, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

Daphne Haas-Kogan, MD

Chief, Enterprise Radiation Oncology, Mass General Brigham; Professor, Harvard Medical School

Roger Hajjar, MD

Director, Gene & Cell Therapy Institute, Mass General Brigham

John Hanna, MD, PhD

Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

Yvonne Hao

Secretary of Economic Development, Commonwealth of Massachusetts

Nobuhiko Hata PhD

Director, Surgical Navigation and Robotics Laboratory, Brigham and Women’s Hospital; Professor of Radiology, Harvard Medical School

Maura Healey

Governor of the Commonwealth of Massachusetts

Elizabeth Henske, MD

Director, Center for LAM Research and Clinical Care, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Leigh Hochberg MD, PhD

Director of Neurotechnology and Neurorecovery, Massachusetts General Hospital; Senior Lecturer on Neurology, Harvard Medical School

Daphne Holt, MD, PhD

Director of the Resilience and Prevention Program, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School

Susan Huang, MD

EVP, Chief Executive, Providence Clinical Network, Providence Southern CA

Keith Isaacson, MD

Director of Minimally Invasive Gynecologic Surgery and Infertility, Newton Wellesley Hospital; Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Ole Isacson, MD-PhD

Founding Director, Neuroregeneration Research Institute, McLean Hospital; Professor of Neurology and Neuroscience, Harvard Medical School

Haim Israel

Head of Global Thematic Investing Research, BofA Global Research

Farouc Jaffer, MD, PhD

Director, Coronary Intervention, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

Russell Jenkins, MD, PhD

Krantz Family Center for Cancer Research, Massachusetts General Hospital; Mass General Cancer Center, Center for Melanoma; Assistant Professor of Medicine, Harvard Medical School

Hadine Joffe, MD

Executive Director of the Connors Center for Women’s Health and Gender Biology; Interim Chair, Department of Psychiatry, Brigham and Women’s Hospital; Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health, Harvard Medical School

Benjamin Kann, MD

Assistant Professor, Brigham and Women’s Hospital & Harvard Medical School

Tatsuo Kawai, MD, PhD

Director of the Legorreta Center for Clinical Transplantation Tolerance, A.Benedict Cosimi Chair in Transplant Surgery, Massachusetts General Hospital; Professor of Surgery, Harvard Medical School

Albert Kim, MD

Assistant Physician, Mass General Cancer Center; Assistant Professor, Harvard Medical School

Roger Kitterman

Senior Vice President, Ventures and Business Development & Licensing, Mass General Brigham Managing Partner, Mass General Brigham Ventures

Lotte Bjerre Knudsen, DMSc

Chief Scientific Advisor, Novo Nordisk

Vesela Kovacheva, MD, PhD

Director of Translational and Clinical Research, Mass General Brigham; Assistant Professor of Anesthesia, Harvard Medical School

Jonathan Kraft

President, The Kraft Group; Board Chair, Massachusetts General Hospital

John Krystal, MD

Chair, Department of Psychiatry, Yale School of Medicine

Daniel Kuritzkes, MD

Chief, Division of Infectious Diseases, Brigham and Women’s Hospital; Harriet Ryan Albee Professor of Medicine, Harvard Medical School

Bruce Levy, MD

Physician-In-Chief and Co-Chair, Department of Medicine, Brigham and Women’s Hospital; Parker B. Francis Professor of Medicine, Harvard Medical School

Katherine Liao, MD

Associate Physician, Department of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital; Associate Professor of Medicine and Biomedical Informatics, Harvard Medical School

David Louis, MD

Enterprise Chief, Pathology, Mass General Brigham Benjamin Castleman Professor of Pathology, Harvard Medical School

Tim Luker, PhD

VP, Ventures & West Coast Head, Eli Lilly

Andrew Luster, MD, PhD

Chief, Division of Rheumatology, Allergy and Immunology; Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; Persis, Cyrus and Marlow B. Harrison Professor of Medicine, Harvard Medical School

Allen Lutz

Health Care Services Analyst, BofA Global Research

Calum MacRae MD, PhD

Vice Chair for Scientific Innovation, Department of Medicine, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Joren Madsen, MD, PhD

Director, MGH Transplant Center; Paul S. Russell/Warner-Lambert Professor of Surgery, Harvard Medical School

Faisal Mahmood, PhD

Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

Peter Marks, MD, PhD

Director, Center for Biologics Evaluation and Research, FDA

Marcela Maus, MD, PhD

Director of Cellular Therapy and Paula O’Keeffe Chair in Cancer Research, Krantz Family Center for Cancer Research and Mass General Cancer Center; Associate Director, Gene and Cell Therapy Institute, Mass General Brigham; Associate Professor, Harvard Medical School

Thorsten Mempel, MD, PhD

Associate Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

Rebecca Mishuris, MD

Chief Medical Information Officer, Mass General Brigham; Member of the Faculty, Harvard Medical School

Pradeep Natarajan, MD

Director of Preventive Cardiology, Paul & Phyllis Fireman Endowed Chair in Vascular Medicine, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

Nawal Nour, MD

Chair, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital; Associate Professor, Kate Macy Ladd Professorship, Harvard Medical School

Heather O’Sullivan, MS, RN, AGNP

President, Mass General Brigham Healthcare at Home

Anne Oxrider

Senior Vice President, Benefits Executive, Bank of America

Claire-Cecile Pierre, MD

Vice President, Community Health Programs, Mass General Brigham; Instructor in Medicine, Harvard Medical School

Richard Pierson III, MD

Scientific Director, Center for Transplantation Sciences, Massachusetts General Hospital; Professor of Surgery, Harvard Medical School

Mark Poznansky, MD, PhD

Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital; Steve and Deborah Gorlin MGH Research Scholar; Professor of Medicine, Harvard Medical School

Yakeel Quiroz, PhD

Director, Familial Dementia Neuroimaging Lab and Director, Multicultural Alzheimer’s Prevention Program, Massachusetts General Hospital; Paul B. and Sandra M. Edgerley MGH Research Scholar; Associate Professor, Harvard Medical School

Heidi Rehm, PhD

Chief Genomics Officer, Massachusetts General Hospital; Professor of Pathology, Harvard Medical School

Leonardo Riella, MD, PhD

Medical Director of Kidney Transplantation, Massachusetts General Hospital; Harold and Ellen Danser Endowed Chair in Transplantation, Harvard Medical School

Jorge Rodriguez, MD

Clinician-investigator, Brigham and Women’s Hospital; Assistant Professor, Harvard Medical School

Adam Ron

Health Care Facilities and Managed Care Analyst, BofA Global Research

David Ryan, MD

Physician-in-Chief, Mass General Brigham Cancer; Professor of Medicine, Harvard Medical School

Michael Ryskin

Life Science Tools & Diagnostics Analyst, BofA Global Research

Alkesh Shah

Head of US Equity Software Research, BofA Global Research

Angela Shen, MD

Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation

Gregory Simon

President, Simonovation

Prabhjot Singh, MD, PhD

Senior Advisor, Strategic Initiatives Peterson Health Technology Institute

Brendan Singleton

Healthcare Equity Capital Markets, BofA Securities

Caroline Sokol, MD, PhD

Assistant Physician, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Daniel Solomon, MD

Matthew H. Liang Distinguished Chair in Arthritis and Population Health, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Scott Solomon, MD

Director, Clinical Trials Outcomes Center; Edward D. Frohlich Distinguished Chair in Cardiovascular Pathophysiology, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Fatima Cody Stanford, MD

Obesity Medicine Physician Scientist, Massachusetts General Hospital; Associate Professor of Medicine and Pediatrics, Harvard Medical School

Shannon Stott, PhD

Associate Investigator, Krantz Family Center for Cancer Research and Mass General Cancer Center; d’Arbeloff Research Scholar, Massachusetts General Hospital; Associate Investigator, Krantz Family Center for Cancer Research Harvard Medical School

Alec Stranahan, PhD

SMid-Cap Biotech Analyst, BofA Global Research

Marc Succi, MD

Executive Director, Mass General Brigham MESH Incubator; Associate Chair of Innovation & Commercialization, Mass General Brigham Radiology; Assistant Professor, Harvard Medical School

Guillermo Tearney, MD, PhD

Principal Investigator, Wellman Center for Photomedicine, Massachusetts General Hospital; Remondi Family Endowed MGH Research Institute Chair; Professor of Pathology, Harvard Medical School

David Ting, MD

Associate Clinical Director for Innovation, Mass General Cancer Center; Associate Professor of Medicine, Harvard Medical School

Raul Uppot, MD

Interventional Radiologist, Massachusetts General Hospital; Associate Professor, Harvard Medical School

Chris Varma, PhD

Co-founder, Chairman & CEO, Frontier Medicines

Kaveeta Vasisht, MD, PharmD

Associate Commissioner, Women’s Health, U.S. Food and Drug Administration

Alexandra-Chloé Villani PhD

Investigator, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Kate Walsh

Secretary of Health and Human Services, State of Massachusetts

David Walt, PhD

Professor of Pathology, Brigham and Women’s Hospital; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School

Jennifer Warner-Schmidt, PhD

Vice President, Scientific Affairs, Transcend Therapeutics

Renee Wegrzyn, PhD

Director, Advanced Research Projects Agency for Health

Christoph Westphal, MD, PhD

General Partner, Longwood Fund

Deborah Wexler, MD

Chief, Diabetes Unit, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

Charlie Yang, PhD

Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

Nathan Yozwiak, PhD

Head of Research, Gene and Cell Therapy Institute, Mass General Brigham

Jason Zemansky, PhD

SMid-Cap Biotech Analyst, BofA Global Research

Alice Zheng, MD

Principal, RH Capital

We continue to confirm more speakers. Please check back regularly for updates.

Read Full Post »

New studies link cell cycle proteins to immunosurveillance of premalignant cells

Curator: Stephen J. Williams, Ph.D.

The following is from a Perspectives article in the journal Science by Virinder Reen and Jesus Gil called “Clearing Stressed Cells: Cell cycle arrest produces a p21-dependent secretome that initaites immunosurveillance of premalignant cells”. This is a synopsis of the Sturmlechener et al. research article in the same issue (2).

Complex organisms repair stress-induced damage to limit the replication of faulty cells that could drive cancer. When repair is not possible, tissue homeostasis is maintained by the activation of stress response programs such as apoptosis, which eliminates the cells, or senescence, which arrests them (1). Cellular senescence causes the arrest of damaged cells through the induction of cyclin-dependent kinase inhibitors (CDKIs) such as p16 and p21 (2). Senescent cells also produce a bioactive secretome (the senescence-associated secretory phenotype, SASP) that places cells under immunosurveillance, which is key to avoiding the detrimental inflammatory effects caused by lingering senescent cells on surrounding tissues. On page 577 of this issue, Sturmlechner et al. (3) report that induction of p21 not only contributes to the arrest of senescent cells, but is also an early signal that primes stressed cells for immunosurveillance.Senescence is a complex program that is tightly regulated at the epigenetic and transcriptional levels. For example, exit from the cell cycle is controlled by the induction of p16 and p21, which inhibit phosphorylation of the retinoblastoma protein (RB), a transcriptional regulator and tumor suppressor. Hypophosphorylated RB represses transcription of E2F target genes, which are necessary for cell cycle progression. Conversely, production of the SASP is regulated by a complex program that involves super-enhancer (SE) remodeling and activation of transcriptional regulators such as nuclear factor κB (NF-κB) or CCAAT enhancer binding protein–β (C/EBPβ) (4).

Senescence is a complex program that is tightly regulated at the epigenetic and transcriptional levels. For example, exit from the cell cycle is controlled by the induction of p16 and p21, which inhibit phosphorylation of the retinoblastoma protein (RB), a transcriptional regulator and tumor suppressor. Hypophosphorylated RB represses transcription of E2F target genes, which are necessary for cell cycle progression. Conversely, production of the SASP is regulated by a complex program that involves super-enhancer (SE) remodeling and activation of transcriptional regulators such as nuclear factor κB (NF-κB) or CCAAT enhancer binding protein–β (C/EBPβ) (4).

Sturmlechner et al. found that activation of p21 following stress rapidly halted cell cycle progression and triggered an internal biological timer (of ∼4 days in hepatocytes), allowing time to repair and resolve damage (see the figure). In parallel, C-X-C motif chemokine 14 (CXCL14), a component of the PASP, attracted macrophages to surround and closely surveil these damaged cells. Stressed cells that recovered and normalized p21 expression suspended PASP production and circumvented immunosurveillance. However, if the p21-induced stress was unmanageable, the repair timer expired, and the immune cells transitioned from surveillance to clearance mode. Adjacent macrophages mounted a cytotoxic T lymphocyte response that destroyed damaged cells. Notably, the overexpression of p21 alone was sufficient to orchestrate immune killing of stressed cells, without the need of a senescence phenotype. Overexpression of other CDKIs, such as p16 and p27, did not trigger immunosurveillance, likely because they do not induce CXCL14 expression.In the context of cancer, senescent cell clearance was first observed following reactivation of the tumor suppressor p53 in liver cancer cells. Restoring p53 signaling induced senescence and triggered the elimination of senescent cells by the innate immune system, prompting tumor regression (5). Subsequent work has revealed that the SASP alerts the immune system to target preneoplastic senescent cells. Hepatocytes expressing the oncogenic mutant NRASG12V (Gly12→Val) become senescent and secrete chemokines and cytokines that trigger CD4+ T cell–mediated clearance (6). Despite the relevance for tumor suppression, relatively little is known about how immunosurveillance of oncogene-induced senescent cells is initiated and controlled.

Source of image: Reen, V. and Gil, J. Clearing Stressed Cells. Science Perspectives 2021;Vol 374(6567) p 534-535.

References

2. Sturmlechner I, Zhang C, Sine CC, van Deursen EJ, Jeganathan KB, Hamada N, Grasic J, Friedman D, Stutchman JT, Can I, Hamada M, Lim DY, Lee JH, Ordog T, Laberge RM, Shapiro V, Baker DJ, Li H, van Deursen JM. p21 produces a bioactive secretome that places stressed cells under immunosurveillance. Science. 2021 Oct 29;374(6567):eabb3420. doi: 10.1126/science.abb3420. Epub 2021 Oct 29. PMID: 34709885.

More Articles on Cancer, Senescence and the Immune System in this Open Access Online Scientific Journal Include

Bispecific and Trispecific Engagers: NK-T Cells and Cancer Therapy

Natural Killer Cell Response: Treatment of Cancer

Issues Need to be Resolved With ImmunoModulatory Therapies: NK cells, mAbs, and adoptive T cells

New insights in cancer, cancer immunogenesis and circulating cancer cells

Insight on Cell Senescence

Immune System Stimulants: Articles of Note @pharmaceuticalintelligence.com

Read Full Post »

Yet another Success Story: Machine Learning to predict immunotherapy response

Curator and Reporter: Dr. Premalata Pati, Ph.D., Postdoc

Immune-checkpoint blockers (ICBs) immunotherapy appears promising for various cancer types, offering a durable therapeutic advantage. Only a number of cases with cancer respond to this therapy. Biomarkers are required to adequately predict the responses of patients. This article evaluates this issue utilizing a system method to characterize the immune response of the anti-tumor based on the entire tumor environment. Researchers build mechanical biomarkers and cancer-specific response models using interpretable machine learning that predict the response of patients to ICB.

The lymphatic and immunological systems help the body defend itself by combating. The immune system functions as the body’s own personal police force, hunting down and eliminating pathogenic baddies.

According to Federica Eduati, Department of Biomedical Engineering at TU/e, “The immune system of the body is quite adept at detecting abnormally behaving cells. Cells that potentially grow into tumors or cancer in the future are included in this category. Once identified, the immune system attacks and destroys the cells.”

Immunotherapy and machine learning are combining to assist the immune system solve one of its most vexing problems: detecting hidden tumorous cells in the human body.

It is the fundamental responsibility of our immune system to identify and remove alien invaders like bacteria or viruses, but also to identify risks within the body, such as cancer. However, cancer cells have sophisticated ways of escaping death by shutting off immune cells. Immunotherapy can reverse the process, but not for all patients and types of cancer. To unravel the mystery, Eindhoven University of Technology researchers used machine learning. They developed a model to predict whether immunotherapy will be effective for a patient using a simple trick. Even better, the model outperforms conventional clinical approaches.

The outcomes of this research are published on 30th June, 2021 in the journal Patterns in an article entitled “Interpretable systems biomarkers predict response to immune-checkpoint inhibitors”.

The Study

  • Characterization of the tumor microenvironment from RNAseq and prior knowledge
  • Multi-task machine-learning models for predicting antitumor immune responses
  • Identification of cancer-type-specific, interpretable biomarkers of immune responses
  • EaSIeR is a tool to predict biomarker-based immunotherapy response from RNA-seq

“Tumor also contains multiple types of immune and fibroblast cells which can play a role in favor of or anti-tumor, and communicates among themselves,” said Oscar Lapuente-Santana, a researcher doctoral student in the computational biology group. “We had to learn how complicated regulatory mechanisms in the micro-environment of the tumor affect the ICB response. We have used RNA sequencing datasets to depict numerous components of the Tumor Microenvironment (TME) in a high-level illustration.”

Using computational algorithms and datasets from previous clinical patient care, the researchers investigated the TME.

Eduati explained

While RNA-sequencing databases are publically available, information on which patients responded to ICB therapy is only available for a limited group of patients and cancer types. So, to tackle the data problem, we used a trick.

All 100 models learned in the randomized cross-validation were included in the EaSIeR tool. For each validation dataset, we used the corresponding cancer-type-specific model: SKCM for the melanoma Gide, Auslander, Riaz, and Liu cohorts; STAD for the gastric cancer Kim cohort; BLCA for the bladder cancer Mariathasan cohort; and GBM for the glioblastoma Cloughesy cohort. To make predictions for each job, the average of the 100 cancer-type-specific models was employed. The predictions of each dataset’s cancer-type-specific models were also compared to models generated for the remaining 17 cancer types.

From the same datasets, the researchers selected several surrogate immunological responses to be used as a measure of ICB effectiveness.

Lapuente-Santana stated

One of the most difficult aspects of our job was properly training the machine learning models. We were able to fix this by looking at alternative immune responses during the training process.

Some of the researchers employed the machine learning approach given in the paper to participate in the “Anti-PD1 Response Prediction DREAM Challenge.”

DREAM is an organization that carries out crowd-based tasks with biomedical algorithms. “We were the first to compete in one of the sub-challenges under the name cSysImmunoOnco team,” Eduati remarks.

The researchers noted,

We applied machine learning to seek for connections between the obtained system-based attributes and the immune response, estimated using 14 predictors (proxies) derived from previous publications. We treated these proxies as individual tasks to be predicted by our machine learning models, and we employed multi-task learning algorithms to jointly learn all tasks.

The researchers discovered that their machine learning model surpasses biomarkers that are already utilized in clinical settings to evaluate ICB therapies.

But why are Eduati, Lapuente-Santana, and their colleagues using mathematical models to tackle a medical treatment problem? Is this going to take the place of the doctor?

Eduati explains

Mathematical models can provide an overview of the interconnection between individual molecules and cells and at the same time predicting a particular patient’s tumor behavior. This implies that immunotherapy with ICB can be personalized in a patient’s clinical setting. The models can aid physicians with their decisions about optimum therapy, it is vital to note that they will not replace them.

Furthermore, the model aids in determining which biological mechanisms are relevant for the biological response.

The researchers noted

Another advantage of our concept is that it does not need a dataset with known patient responses to immunotherapy for model training.

Further testing is required before these findings may be implemented in clinical settings.

Main Source:

Lapuente-Santana, Ó., van Genderen, M., Hilbers, P. A., Finotello, F., & Eduati, F. (2021). Interpretable systems biomarkers predict response to immune-checkpoint inhibitorsPatterns, 100293. https://www.cell.com/patterns/pdfExtended/S2666-3899(21)00126-4

Other Related Articles published in this Open Access Online Scientific Journal include the following:

Inhibitory CD161 receptor recognized as a potential immunotherapy target in glioma-infiltrating T cells by single-cell analysis

Reporter: Dr. Premalata Pati, Ph.D., Postdoc

https://pharmaceuticalintelligence.com/2021/02/20/inhibitory-cd161-receptor-identified-in-glioma-infiltrating-t-cells-by-single-cell-analysis-2/

Immunotherapy may help in glioblastoma survival

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

https://pharmaceuticalintelligence.com/2019/03/16/immunotherapy-may-help-in-glioblastoma-survival/

Deep Learning for In-silico Drug Discovery and Drug Repurposing: Artificial Intelligence to search for molecules boosting response rates in Cancer Immunotherapy: Insilico Medicine @John Hopkins University

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/07/17/deep-learning-for-in-silico-drug-discovery-and-drug-repurposing-artificial-intelligence-to-search-for-molecules-boosting-response-rates-in-cancer-immunotherapy-insilico-medicine-john-hopkins-univer/

Machine Learning (ML) in cancer prognosis prediction helps the researcher to identify multiple known as well as candidate cancer diver genes

Curator and Reporter: Dr. Premalata Pati, Ph.D., Postdoc

https://pharmaceuticalintelligence.com/2021/05/04/machine-learning-ml-in-cancer-prognosis-prediction-helps-the-researcher-to-identify-multiple-known-as-well-as-candidate-cancer-diver-genes/

AI System Used to Detect Lung Cancer

Reporter: Irina Robu, PhD

https://pharmaceuticalintelligence.com/2019/06/28/ai-system-used-to-detect-lung-cancer/

Cancer detection and therapeutics

Curator: Larry H. Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2016/05/02/cancer-detection-and-therapeutics/

Read Full Post »

Older Posts »